Neuroprotective effects of flavonoids and polyphenols

1. A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders
2. A bird’s-eye view of the multiple biochemical mechanisms that propel pathology of Alzheimer’s disease: recent advances and mechanistic perspectives on …
3. A blueberry extract-supplemented diet rescues phenotypes in drosophila melanogaster models of parkinson disease
4. A Comparative Study on the Phenolic Composition and Biological Activities of Morus alba L. Commercial Samples
5. A Comparison of the Antioxidant Activity with the Total Phenolic and Total flavonoid contents of the Leaves and Stem-bark of Anogeissus leiocarpa (DC.) Guill& Pirr …
6. A comprehensive database and analysis framework to incorporate multiscale data types and enable integrated analysis of bioactive polyphenols
7. A comprehensive review on phytochemistry, pharmacology, and flavonoid biosynthesis of Scutellaria baicalensis
8. A Current Understanding of Alzheimer’s Disease and the Prospects of Phytopharmacological Intervention as a Management Strategy
9. A meta-analysis of tea drinking and risk of Parkinson’s disease
10. A molecular approach in drug development for Alzheimer’s disease
11. A Narrative Review of Lifestyle Factors Associated with Parkinson’s Disease Risk and Progression
12. A Novel GSK3β Inhibitor Reduces Tau Pathology in Alzheimer’s Disease
13. A Paradigm Shift to Prevent and Treat Alzheimer’s Disease: From Monotargeting Pharmaceuticals to Pleiotropic Plant Polyphenols
14. A pharmacological appraisal of neuroprotective and neurorestorative flavonoids against Neurodegenerative diseases
15. A review of antioxidant and pharmacological properties of phenolic compounds in Acacia confusa
16. A Review of Antioxidants and Alzheimer
17. A review of antioxidants and Alzheimer’s disease
18. A review of genome mutation and Alzheimer’s disease
19. A review on cholinesterase inhibitors for Alzheimer’s disease
20. A Review on Current Strategies and Future Perspective in Respect to Alzheimer’s Disease Treatment
21. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer’s and Parkinson’s diseases
22. A Review on Medicinal Plants for Alzheimer’s disease
23. A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions
24. A review on potential mechanisms of Terminalia chebula in Alzheimer’s disease
25. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer’s disease
26. A review on the beneficial effects of tea polyphenols on human health
27. A review on the status of the phenolic compounds and antioxidant capacity of the flour: Effects of cereal processing
28. A review–probable mechanism of action of curcumin for the treatment of Alzheimer disease (AD)
29. A review: inflammatory process in Alzheimer’s disease, role of cytokines
30. A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer’s disease mouse model
31. A Study on the Role of Mimosa Pudica (Thottar Chinungi) on the Experimental Models of Parkinsonism (Nadukku Vatham)
32. A synopsis on the linkage between age-related dementias and vascular disorders
33. A systematic review on the role of natural products in modulating the pathways in Alzheimer’s disease
34. Acacetin—A simple flavone exhibiting diverse pharmacological activities
35. Accumulation of citrus flavanones in bovine milk following citrus pulp incorporation into the diet of dairy cows
36. Acetyl-cholinesterase Inhibition by Extracts and Isolated Flavones from Linaria reflexa Desf. (Scrophulariaceae)
37. Acetylated flavonoid Glycosides Potentiating NGF Action from Scoparia dulcis
38. Activation of pro‐survival Akt and ERK1/2 signalling pathways underlie the anti‐apoptotic effects of flavanones in cortical neurons
39. Acute effects of flavonoid-rich blueberry on cognitive and vascular function in healthy older adults
40. Adult‐onset brain tumors and neurodegeneration: Are polyphenols protective?
41. Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer’s disease
42. Advances in multi-functional ligands and the need for metal-related pharmacology for the management of Alzheimer disease
43. Advances in research on active constituents of Chinese materia medica in treatment of Alzheimer’s disease [J]
44. Agathisflavone, a flavonoid derived from Poincianella pyramidalis (Tul.), enhances neuronal population and protects against glutamate excitotoxicity
45. Age-related cognitive impairment as a sign of geriatric neurocardiovascular interactions: may polyphenols play a protective role?
46. Aging risk factors and Parkinson’s disease: contrasting roles of common dietary constituents
47. Alcohol Consumption in Predementia and dementia Syndromes
48. Alcohol intake and risk of dementia
49. Alcohol, wine and mental health: focus on dementia and stroke
50. Alcoholic beverages and incidence of dementia: 34-year follow-up of the prospective population study of women in Göteborg
51. Almond, hazelnut and walnut, three nuts for neuroprotection in Alzheimer’s disease: A neuropharmacological review of their bioactive constituents
52. Alpha-secretase ADAM10 regulation: insights into Alzheimer’s disease treatment
53. Alpha-Synuclein and synuceinopathies as related to Parkinson’s disease
54. Alpha-synuclein oligomers—neurotoxic molecules in Parkinson’s disease and other Lewy body disorders
55. Altered Micro-RNA Regulation and Neuroprotection Activity of Eremostachys labiosiformis in Alzheimer’s Disease Model
56. Alzheimer’s and Parkinson’s Disease Novel Therapeutic Target: The Mitochondrial Pyruvate Carrier-Ligand Docking to Screen Natural Compounds Related to Classic …
57. Alzheimer’s Dementia: Can It Be Prevented?
58. Alzheimer’s disease (AD) genes: Enrichment in cancer genes and those related to comorbid conditions, risk factors (pollution and pathogens) or beneficial agents …
59. Alzheimer’s Disease & Treatment
60. Alzheimer’s Disease & Treatment
61. Alzheimer’s Disease & Treatment
62. Alzheimer’s Disease & Treatment, Vol. 1
63. Alzheimer’s disease and antioxidant therapy: how long how far?
64. Alzheimer’s disease and its current treatments; Is there a possibility for a cure
65. Alzheimer’s Disease and Metal Contamination: Aspects on Genotoxicity
66. Alzheimer’s disease and natural products: Future regimens emerging from nature
67. Alzheimer’s disease and other Neurodegenerative disorders
68. Alzheimer’s Disease and Oxidative Stress
69. Alzheimer’s Disease and Parkinson’s Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and …
70. Alzheimer’s Disease and the Main Aspects-Literature Review
71. Alzheimer’s DISEASE AND THE MICROBIOME
72. Alzheimer’s disease as oligomeropathy
73. Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
74. Alzheimer’s Disease Theranostics
75. Alzheimer’s disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention.
76. Alzheimer’s Disease, Drosophila melanogaster and Polyphenols
77. Alzheimer’s disease, neuroinflammation and the influence of different combinations of nutrients
78. Alzheimer’s disease: A challenge in managing with certain medicinal plants-Areview
79. Alzheimer’s disease: a journey from amyloid peptides and oxidative stress, to biomarker technologies and disease prevention strategies—gains from AIBL …
80. Alzheimer’s Disease: An Approach for Non-Pharmacological Therapies
81. Alzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic tools
82. Alzheimer’s Disease: Early Diagnosis & Fundamental Therapeutics
83. Alzheimer’s disease: from pathology to therapeutic approaches
84. Alzheimer’s disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms
85. Alzheimer’s disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the …
86. Alzheimers Disease & Parkinsonism
87. Ameliorating effect of ethanol leaf extract of Ficus hispida Linn. on amyloid beta Aβ (25-35) induced cognitive deficits and oxidative stress in Alzheimer’s mice
88. Amelioration of 6-Hydroxydopamine-Lesion Induced Neurotoxicity by Different Extracts of Ocimum sanctum Leaves in Rodent Model of Parkinson’s Disease
89. Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer’s type
90. Amentoflavone Ameliorates Aβ1–42-Induced Memory Deficits and oxidative stress in Cellular and Rat Model
91. Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson’s disease model mice through PI3K/Akt and ERK signaling pathways
92. Amentoflavone suppresses amyloid β1–42 neurotoxicity in Alzheimer’s disease through the inhibition of pyroptosis
93. AMP‐activated protein kinase: a potential player in Alzheimer’s disease
94. Amyloid A-Beta Peptide: In-Cell Studies and Mechanism of Polyphenol-Based Inhibition to Aggregation
95. Amyloid precursor protein‐mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer’s disease
96. Amyloid β-Peptide (1–42)-Induced oxidative stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression
97. Amyloid β-protein assembly as a therapeutic target of Alzheimer’s disease
98. Amyloid‐β deposition in Alzheimer transgenic mice is associated with oxidative stress
99. An alternative approach to drug discovery for Alzheimer’s disease dementia
100. An Evaluation of Cholesterol-lowering Effect of Soy Protein and Isoflavones on Postmenopausal Women and Hypercholesterolemic Humans.
101. An Overview of Parkinson’s Disease and Oxidative Stress: Herbal Scenario
102. An overview of the possible therapeutic role of SUMOylation in the treatment of Alzheimer’s disease
103. An overview on global trends in nanotechnological approaches for Alzheimer therapy
104. An overview on potential neuroprotective compounds for management of Alzheimer’s disease
105. An overview on therapeutics attenuating amyloid β level in Alzheimer’s disease: Targeting neurotransmission, inflammation, oxidative stress and enhanced …
106. An update on plant-originated treatment for Alzheimer’s disease
107. An updated review on Anti-Alzheimer’s herbal drugs
108. Analgesic and acetylcholinesterase inhibition potential of polyphenols from Scolopia crenata (Flacourtiaceae): An endemic medicinal plant of India
109. Analysis of amino acid and phenolic content in honey by UPLC-ESI-MS/MS
110. Analysis of technological developments in the treatment of Alzheimer’s disease through patent documents
111. Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson’s Disease
112. Anesthesia Implications of the Use of Essential Oils in Alzheimer’s Dementia
113. Animal models of Parkinson’s disease: a gateway to therapeutics?
114. Anthocyanins Potentially Contribute to Defense against Alzheimer’s Disease
115. Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer’s type
116. Anti-acetylcholinesterase and antioxidant activities and HPLC-MS analysis of polyphenol from extracts of Nelsonia canescens (Lam.) Spreng.
117. Anti-adipogenic Effect of a Dietary flavonoid Fisetin in 3T3-L1 Cells
118. Anti-aging and anti-aggregation properties of polyphenolic compounds in C. elegans
119. Anti-Alzheimer potential of Green Moong Bean
120. Anti-Alzheimer’s studies on β-sitosterol isolated from Polygonum hydropiper L.
121. Anti-amnesic Effect of Leea indica Extract in Scopolamine-induced Amnesia of Alzheimer’s Type in Rats
122. Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer’s β-amyloid fibrils in vitro
123. Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer’s disease
124. Anti-amyloidogenic properties of some phenolic compounds
125. Anti-Demential Effect of EGB 761 on dementia Induced Wistar Rats
126. Anti-Inflammatory Agents in Parkinson’s Disease
127. Anti-inflammatory and immune therapy for Alzheimer’s disease: current status and future directions
128. Anti-inflammatory and immunomodulatory properties of dietary flavonoids
129. Anti-inflammatory Effects of flavonoid Compounds on TNBS-induced Acute Colitis in Rats
130. Anti-inflammatory effects of flavonoids in Neurodegenerative disorders
131. Anti-inflammatory Effects of O-methylated Flavonoid
132. Anti-inflammatory, anti-diabetic, and anti-Alzheimer’s effects of prenylated flavonoids from Okinawa propolis: an investigation by experimental and computational …
133. Anti-inflammatory, immunomodulatory, and prebiotic properties of dietary flavonoids
134. Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer’s disease
135. Anti-Parkinson potential of silymarin: mechanistic insight and therapeutic standing
136. Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models?
137. Antiaging Interventions: An Insight into Polyphenols and Brain Aging
138. Antiapoptotic role of Agaricus blazei extract in rodent model of Parkinson’s disease
139. Antidementic activity of Brassica oleracea l. var. Italica (brassicaceae) flower on memory deficit in young male rats
140. Antidepressant flavonoids and their relationship with oxidative stress
141. Antihepatotoxic, nephroprotective, and antioxidant activities of phenolic compounds from Satureja macrostema leaves against carbon tetrachloride-induced hepatic …
142. Antioxidant activity and total phenolic content of ethanolic extract of Caesalpinia bonducella seeds
143. Antioxidant activity of selected phenols estimated by ABTS and FRAP methods.
144. Antioxidant Activity of Wine Polyphenols for Alzheimer Prevention
145. Antioxidant and anti‐inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental …
146. Antioxidant and Anticholinesterase Activities of Macrosphyra Longistyla (DC) Hiern Relevant in the Management of Alzheimer’s Disease
147. Antioxidant and Choline Esterase Inhibitory Activity of Phenolic Rich Extracts from Bombax ceiba L. Flowers.
148. Antioxidant and neuroprotective Effects of Synthetic Curcumin Analogues and Natural Phenolics
149. Antioxidant and neuroprotective properties of blueberry polyphenols: a critical review
150. Antioxidant and pro-oxidant effects of polyphenolic compounds and structure-activity relationship evidence
151. Antioxidant Capacity and Behavioral Relevance of a Polyphenolic Extract of Chrysanthellum americanum in a Rat Model of Irritable Bowel Syndrome
152. Antioxidant Capacity is Decreased in Alzheimer’s Disease and Mild Cognitive Impairment Patients
153. ANTIOXIDANT EFFECT OF flavonoids IN Neurodegenerative DISEASES.
154. Antioxidant effect of flavonoids present in Euterpe oleracea Martius and Neurodegenerative diseases: A literature review
155. Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach
156. Antioxidant Nutraceuticals and Parkinson’s Disease
157. Antioxidant phenolic constituents from Parthenocissus tricuspidata
158. Antioxidant plant polyphenols and cognitive disorders
159. ANTIOXIDANT PROPERTIES OF A Ginkgo biloba LEAF EXTRACT (EGb 761) IN ANIMAL MODELS OF Alzheimer’s AND Parkinson’s DISEASES.
160. Antioxidant properties of Crocus sativus L. and its constituents and relevance to Neurodegenerative diseases; focus on Alzheimer’s and Parkinson’s disease
161. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease
162. Antioxidant therapy in Alzheimer’s disease: theory and practice
163. Antioxidants and Alzheimer’s disease: from bench to bedside (and back again)
164. Antioxidants and dementia risk: consideration through a cerebrovascular perspective
165. Antioxidants as a potential therapy against age-related Neurodegenerative diseases: amyloid beta toxicity and Alzheimer’s disease
166. Antioxidants in the Prevention and Treatment of Alzheimer’s Disease
167. Antioxidants, diet, polyphenols and dementia
168. Apolipoprotein ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity
169. Apples and their products effect on neurodegeneration and Alzheimer’s disease
170. Application of yeast to study the tau and amyloid-β abnormalities of Alzheimer’s disease
171. Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
172. Applying transcriptomic and proteomic knowledge to Parkinson’s disease drug discovery
173. Approaches Based on Cholinergic Hypothesis and Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease
174. Are polyphenols strong dietary agents against neurotoxicity and neurodegeneration?
175. Arecanut (Areca catechu L) decreases Alzheimer’s disease symptoms: Compilation of research works
176. Artemisia amygdalina Upregulates Nrf2 and Protects Neurons Against oxidative stress in Alzheimer Disease
177. Asparagus cochinchinensis stimulates release of nerve growth factor and abrogates oxidative stress in the Tg2576 model for Alzheimer’s disease
178. Assessment of anticholinesterase activities and antioxidant potentials of Anisomeles indica relevant to the treatment of Alzheimer’s disease
179. Assessment of the effect of selected African plants on an in vitro model of Parkinson’s disease
180. association of tea consumption with risk of Alzheimer’s disease and anti-beta-amyloid effects of tea
181. ATR-IR study of the mechanism of aluminum chloride induced Alzheimer’s disease; curative and protective effect of Lipidium sativum water extract on …
182. Attention-deficit/hyperactivity disorder–unifying mechanism involving antioxidant therapy: Phenolics, reactive oxygen species, and oxidative stress
183. Attenuation of iNOS and COX2 by blueberry polyphenols is mediated through the suppression of NF-κB activation
184. Auraptene Mitigates Parkinson’s Disease-Like Behavior by Protecting Inhibition of Mitochondrial Respiration and Scavenging Reactive Oxygen Species
185. Autophagy in Alzheimer’s disease and promising modulatory effects of herbal medicine
186. Autophagy, polyphenols and healthy ageing
187. Aβ propagation and strains: implications for the phenotypic diversity in Alzheimer’s disease
188. BACE inhibitors as potential therapeutics for Alzheimer’s disease
189. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease
190. Baicalein reduces β‐amyloid and promotes nonamyloidogenic amyloid precursor protein processing in an Alzheimer’s disease transgenic mouse model
191. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease
192. Behavioral and neurochemical alterations induced by vanillin in a mouse model of Alzheimer’s disease
193. Beneficial effect of flavone derivatives on Aβ-induced memory deficit is mediated by peroxisome proliferator-activated receptor γ coactivator 1α: a comparative study
194. Beneficial effect of the flavonoid luteolin on neuroinflammation
195. Beneficial effects of flavonoids against Parkinson’s disease
196. Beneficial Effects of flavonoids on Neurological Disorders
197. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson’s disease: the role of glia and NRf2 regulation
198. Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration
199. Beneficial effects of phenolic compounds from fruit and vegetables in Neurodegenerative diseases
200. Beneficial effects of polyphenols on chronic diseases and ageing
201. Beneficial properties of natural phenols: highlight on protection against pathological conditions associated with amyloid aggregation
202. Benefits from dietary polyphenols for brain aging and Alzheimer’s disease
203. Berry phenolics and their antioxidant activity
204. Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer’s disease
205. Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain
206. Biflavonoids as potential small molecule therapeutics for Alzheimer’s disease
207. Bioactive composition and promising health benefits of natural food flavors and colorants: potential beyond their basic functions
208. Bioactive flavonoids and Catechols as Hif1 and Nrf2 Protein Stabilizers-Implications for Parkinson’s Disease
209. Bioactivity of olive oil phenols in neuroprotection
210. Bioanalytical Approach to the Interaction of Novel sym-Triazine Derivatives with Alzheimer’s Disease Biomarkers
211. Bioanalytical Approaches to Investigate Antioxidant Molecules and Nucleic Acid-Protein Interactions in Alzheimer’s Disease
212. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts
213. Bioavailability and pharmaco-therapeutic potential of luteolin in overcoming Alzheimer’s disease
214. Bioavailability of dietary polyphenols: Factors contributing to their clinical application in CNS diseases
215. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update
216. Biochanin-A ameliorates behavioural and neurochemical derangements in cognitive-deficit mice for the betterment of Alzheimer’s disease
217. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis
218. Biological reactivity of polyphenolic− glutathione conjugates
219. Biopharmaceutical Monotargeting versus ‘Universal Targeting’of Late-Onset Alzheimer’s Disease Using Mixtures of Pleiotropic Natural Compounds
220. Biophenols pharmacology against the amyloidogenic activity in Alzheimer’s disease
221. Biophenols: Enzymes (β-secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (Olea europaea L.)
222. Biophysical characteristics of proteins and living cells exposed to the green tea polyphenol epigallocatechin-3-gallate (EGCg): review of recent advances from …
223. Bioprocessing Strategies to Enhance L-DOPA and Phenolic Bioactives in the Fava Bean (Vicia Faba)
224. Biosynthesized metal nanoparticles as potential Alzheimer’s disease therapeutics
225. Black tea theaflavins inhibit formation of toxic amyloid-β and α-synuclein fibrils
226. Blanching alters the phenolic constituents and in vitro antioxidant and anticholinesterases properties of fireweed (Crassocephalum crepidioides)
227. Blueberry polyhphenols and neuroprotection
228. Blueberry polyphenols and neuroprotection
229. Botanical phenolics and brain health
230. Botanics: a potential source of new therapies for Alzheimer’s disease
231. Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer’s disease
232. Brain food for Alzheimer-free ageing: focus on herbal medicines
233. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease
234. Brain iron accumulation in Parkinson’s disease: An investigation of genes related to iron metabolism and homeostasis and dietary behavior data in a case …
235. Brain iron metabolism dysfunction in Parkinson’s disease
236. Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson’s disease
237. C0550 Neuroinflammation in Alzheimer’s Disease: The Preventive and Therapeutic Potential of Polyphenolic Nutraceuticals
238. Caffeic acid attenuates oxidative stress, learning and memory deficit in intra-cerebroventricular streptozotocin induced experimental dementia in rats
239. Can co-activation of Nrf2 and neurotrophic signaling pathway slow Alzheimer’s disease?
240. Can consuming flavonoids restore old microglia to their youthful state?
241. Can we prevent Parkinson’s disease
242. Cannabis Flavonoids—Antioxidant & Anti-Inflammatory Benefits
243. Carbohydrates and Glycomimetics in Alzheimer’s Disease Therapeutics and Diagnosis
244. Carbon nanomaterials and amyloid beta interactions: Possible potentials in the detection and treatment of Alzheimer’s disease
245. Catechin polyphenols: neurodegeneration and neuroprotection in Neurodegenerative diseases
246. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG)
247. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (‐)‐epigallocatechin‐3‐gallate: implications for Neurodegenerative diseases
248. Cellular and molecular aspects of Parkinson treatment: future therapeutic perspectives
249. Cellular and molecular mechanisms of antioxidants in Parkinson’s disease
250. Cellular phenotypes as inflammatory mediators in Parkinson’s disease: interventional targets and role of natural products
251. Cerebral area differential redox response of neonatal rats to selenite-induced oxidative stress and to concurrent administration of highbush blueberry leaf polyphenols
252. Cerebral hypoperfusion and glucose hypometabolism: key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer’s …
253. Challenges for research on polyphenols from foods in Alzheimer’s disease: bioavailability, metabolism, and cellular and molecular mechanisms
254. Champagne wine polyphenols protect primary cortical neurons against peroxynitrite-induced injury
255. Changing paradigm from one target one ligand towards multi-target directed ligand design for key drug targets of Alzheimer disease: an important role of in silico …
256. Characterization of Copper Interactions with Alzheimer Amyloid β Peptides: Identification of an Attomolar‐Affinity Copper Binding Site on Amyloid β1‐42
257. Characterization of Copper Interactions with Alzheimer Amyloid β Peptides: Identification of an Attomolar‐Affinity Copper Binding Site on Amyloid β1‐42
258. Characterization of neurotoxic effects of NMDA and the novel neuroprotection by phytopolyphenols in mice.
259. Characterization of phenolic compounds using UPLC–HRMS and HPLC–DAD and anti-cholinesterase and anti-oxidant activities of Trifolium repens L. leaves
260. CHARACTERIZATION OF THE neuroprotective ACTIVITY OF THE polyphenol (-)-EPIGALLOCATECHIN-3-GALLATE IN THE BRAIN
261. Charnoly body as a novel biomarker of nutritional stress in Alzheimer’s Disease
262. Chemical fingerprint of Bacopa monnieri L. and Rosmarinus officinalis L. and their neuroprotective activity against Alzheimer’s disease in rat model’s putative …
263. Chemical structures, bioactivities and molecular mechanisms of citrus polymethoxyflavones
264. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson’s disease
265. Chocolate and the brain: neurobiological impact of cocoa flavanols on cognition and behavior
266. Chocolate/Cocoa Polyphenols and Oxidative Stress
267. Cholinesterase inhibitors as Alzheimer’s therapeutics
268. Chroman-like cyclic prenylflavonoids promote neuronal differentiation and neurite outgrowth and are neuroprotective
269. Chronic dietary supplementation of 4% figs on the modification of oxidative stress in Alzheimer’s disease transgenic mouse model
270. Chronic Hypoxia Alters mRNA Expression of the Genes Related to Alzheimer’s Disease in Primary Neuronal Cells
271. Chronic neuroinflammation in Alzheimer’s disease: new perspectives on animal models and promising candidate drugs
272. Chronic treatment with resveratrol, a natural polyphenol found in grapes, alleviates oxidative stress and apoptotic cell death in ovariectomized female rats subjected to …
273. Cinnamon, a promising prospect towards Alzheimer’s disease
274. Citrus Fruit Polyphenols and Flavonoids: Applications to Psychiatric Disorders
275. Clinical benefit and preservation of flavonols in dark chocolate manufacturing
276. Clinical Development of a Novel Parkinsonian Drug in USA
277. Cocoa and dark chocolate polyphenols: from biology to clinical applications
278. Cocoa flavanols, exercise and the brain
279. Cocoa Powder Triggers neuroprotective and Preventive Effects in a Human Alzheimer 0 s Disease Model by Modulating BDNF Signaling Pathway
280. Cocoa powder triggers neuroprotective and preventive effects in a human Alzheimer’s disease model by modulating BDNF signaling pathway
281. Coffee phenolic phytochemicals and kaempferol protect against oxidative damage of neuronal cells and memory impairments
282. Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review
283. Cognitive Function and Consumption of Fruit and Vegetable Polyphenols in a Young Population: Is There a Relationship?
284. Cognitive stimulation with leisure activities for prevention of cognitive decline and dementia: The aktiva study
285. Cognitive-enhancing effect of quercetin in a rat model of Parkinson’s disease induced by 6-hydroxydopamine
286. Combating oxidative stress disorders with citrus flavonoid: Naringenin
287. Combination of EPA with carotenoids and polyphenol synergistically attenuated the transformation of microglia to M1 phenotype via inhibition of NF-κB
288. Commentary: The flavonoid Baicalein Rescues Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer’s Disease
289. Comparative analysis of total phenolic and total flavonoid contents, rutin, tannins and antioxidant capacity in Apiaceae and Lamiaceae families
290. Comparative antioxidant activity of twenty traditional Indian medicinal plants and its correlation with total flavonoid and phenolic content
291. Comparative evaluation of Helichrysi flos herbal extracts as dietary sources of plant polyphenols, and macro-and microelements
292. Comparative evaluation of the antioxidant and anti-Alzheimer’s disease potential of coumestrol and puerarol isolated from pueraria lobata using molecular modeling …
293. Comparative study on the inhibitory effect of caffeic and chlorogenic acids on key enzymes linked to Alzheimer’s disease and some pro-oxidant induced oxidative …
294. Comparison of protective effects of four polyphenols on neuropathology and behavior of APP/PS1-21 transgenic mice, a model of Alzheimer’s disease
295. Comparison of Three Amyloid Assembly Inhibitors: The Sugar scyllo-Inositol, the polyphenol Epigallocatechin Gallate, and the Molecular Tweezer CLR01
296. Complementary Therapies for Parkinson’s Disease: What’s Promoted, Rationale, Potential Risks and Benefits
297. Compositional Changes in Anthocyanins, Flavonols, and Ellagitannins in Processed Blackberries
298. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies
299. Computational approaches to the investigation of proteins involved in Parkinson’s Disease
300. Computational modeling of multi-target-directed inhibitors against Alzheimer’s disease
301. Computer-aided structure-based design of multitarget leads for Alzheimer’s disease
302. Conjugates of catecholamines with cysteine and GSH in Parkinson’s disease: possible mechanisms of formation involving reactive oxygen species
303. Conservative iron chelation for Neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis
304. Considerations for the use of polyphenols as therapies in Neurodegenerative diseases
305. Consumption of anthocyanin-rich cherry juice for 12 weeks improves memory and cognition in older adults with mild-to-moderate dementia
306. Consumption of fig fruits grown in Oman can improve memory, anxiety, and learning skills in a transgenic mice model of Alzheimer’s disease
307. Consumption of polyphenol plants may slow aging and associated diseases
308. Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for …
309. Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for …
310. Copper-Catalyzed Oxidative Esterification of 2-Carbonyl Substituted Phenols with Alcohols
311. Correlation between the polyphenol content and antioxidant effect of Cynara scolymus L. mother tincture
312. Critical Evaluation of Current Alzheimer′ s Drug Discovery (2018-19) & Futuristic Alzheimer drug model approach
313. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease
314. Curcumin and Apigenin–novel and promising therapeutics against chronic neuroinflammation in Alzheimer’s disease
315. Curcumin and Its Nanoformulations as Therapeutic for Alzheimer’s Disease
316. Curcumin exposure induces expression of the Parkinson’s disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells
317. Curcumin has potent anti‐amyloidogenic effects for Alzheimer’s β‐amyloid fibrils in vitro
318. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models
319. Curcumin prevents and ameliorates biochemical and behavioral toxicities of MPTP in C57Bl/6J mice: its potential use in preventing and treating parkinsonism
320. Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits α-synuclein oligomer formation: relevance to Parkinson’s disease
321. Current Alzheimer’s management with berries fruits therapy
322. CURRENT Alzheimer’s MANAGEMENT WITH DIETARY SEEDS THERAPY
323. Current and emerging pharmacological targets for the treatment of Alzheimer’s disease
324. Current and emerging therapeutic targets of Alzheimer’s disease for the design of multi-target directed ligands
325. Current and investigational drugs for treatment of Alzheimer’s disease
326. Current concepts on selected plant secondary metabolites with promising inhibitory effects against enzymes linked to Alzheimer’s disease
327. Current evidence on the effect of dietary polyphenols intake on chronic diseases
328. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson’s disease
329. Current perspectives and mechanisms of relationship between intestinal microbiota dysfunction and dementia: a review
330. Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease
331. Current status of metals as therapeutic targets in Alzheimer’s disease
332. Cytological profiling of natural product scaffolds libraries for Parkinson’s disease
333. Cytoprotection by Achyrocline satureioides (Lam) DC and some of its main flavonoids against oxidative stress
334. Cytoprotective effects of phenolic antioxidants and essential fatty acids in human blood monocyte and neuroblastoma cell lines: Surrogates for neurological damage in …
335. De B. Acetylcholinesterase inhibitory properties of black tea and its polyphenolic components
336. Defective insulin signalling, mediated by inflammation, connects obesity to Alzheimer disease; relevant pharmacological therapies and preventive dietary …
337. dementia IN SURINAME
338. Dementia, preclinical studies in neurodegeneration and its potential for translational medicine in South America
339. Design and characterization of enzymatic deglycosylation systems to produce drugs against Alzheimer’s disease
340. Design and development of novel irreversible GSK-3β inhibitors to address Alzheimer’s disease
341. Design and Molecular dynamic investigations of 7, 8-Dihydroxyflavone Derivatives as potential neuroprotective Agents Against Alpha-synuclein
342. Design and Molecular dynamic Investigations of 7, 8-Dihydroxyflavone Derivatives as Potential neuroprotective Agents Against Alpha-synuclein
343. Design and systhesis of nanoparticles for therapy and imaging of Alzheimer’s disease
344. Design of Multi-target Directed Ligands as a Modern Approach for the Development of Innovative Drug Candidates for Alzheimer’s Disease
345. Design, Synthesis and Biological Assessment of Ferulic Acid Derivatives as Inhibitors of β-Amyloid Oligomerization in Alzheimer’s Disease
346. Design, synthesis and biological evaluation of 3-piperazinecarboxylate sarsasapogenin derivatives as potential multifunctional anti-Alzheimer agents
347. Design, synthesis and biological evaluation of scutellarein derivatives as potential anti-Alzheimer’s disease candidates based on metabolic mechanism
348. Design, synthesis and evaluation of 4′-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer’s disease treatment
349. Design, synthesis and evaluation of chalcone Mannich base derivatives as multifunctional agents for the potential treatment of Alzheimer’s disease
350. Designing multi-targeted therapeutics for the treatment of Alzheimer’s disease
351. Destabilization of Alzheimer’s Aβ42 protofibrils with a novel drug candidate wgx-50 by molecular dynamics simulations
352. Determination of Flavonoids
353. Determination of total flavonoid content of different parts of Garcinia cowa
354. Development and application of nano-flavor-drug carriers in Neurodegenerative diseases
355. Development and validation of analytical methods for the identification and quantification of phenolic compounds from Euterpe oleracea fruits
356. Development of a grape seed polyphenolic extract with anti‐oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies
357. Development of Electrochemical Sensors for the Analysis of Therapeutic Compounds and Proteases related to Alzheimer’s disease
358. Development of multifunctional molecules as potential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the …
359. Development of tau aggregation inhibitors for Alzheimer’s disease
360. Development of technologies for the production of polyphenolic nutraceuticals from muscadine grapes and rabbiteye blueberries
361. Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches
362. Diabetes and Alzheimer’s disease: can tea phytochemicals play a role in prevention?
363. Diet and brain health: which role for polyphenols?
364. Diet And Lifestyle Guidelines And Desirable Levels Of Risk Factors And Protective Factors For Prevention Of Dementia-A Scientific Statement From Joint …
365. Diet and medical foods in Parkinson’s disease
366. Diet and Nutrition in Alzheimer’s Disease and Healthy Aging
367. Diet and Nutrition in Alzheimer’s Disease and Healthy Aging
368. Diet and nutrition in dementia and cognitive decline
369. Diet and the Risk of Parkinson’s Disease—Research Suggests Dietary Interventions May Prevent It and Lessen Symptom Severity By Densie Webb, PhD, RD
370. Diet, nutrients and metabolism: cogs in the wheel driving Alzheimer’s disease pathology?
371. Dietary coconut and amyloid beta metabolism in the pathogenesis of Alzheimer’s disease
372. Dietary Directions Against dementia Disorders
373. Dietary factors in the etiology of Parkinson’s disease
374. Dietary fatty acids and predementia syndromes
375. Dietary fatty acids intake: possible role in cognitive decline and dementia
376. Dietary fatty acids, cognitive decline, and dementia
377. Dietary flavonoid intake in older adults: how many days of dietary assessment are required and what is the impact of seasonality?
378. Dietary flavonoid intake to reduce the risk of chronic diseases
379. Dietary flavonoids as potential neuroprotectants
380. Dietary flavonoids Interaction with CREB-BDNF Pathway: An Unconventional Approach for Comprehensive Management of Epilepsy
381. Dietary intake of natural antioxidants: vitamins and polyphenols
382. Dietary lipids and their oxidized products in Alzheimer’s disease
383. Dietary modifications in Parkinson’s disease: A neuroprotective intervention?
384. Dietary modulation of oxidative stress in Alzheimer’s disease
385. Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity
386. Dietary phenolics in apples and cider and their bioavailability in healthy humans and subjects with an ileaostomy
387. Dietary Plant Lectins May be an ‘Unknown Etiology’in Parkinson’s Disease and Dietary Bioactive Compounds Affect Lifespan and Fat Storage Aspects of …
388. Dietary polyphenols and mitochondrial function: role in health and disease
389. Dietary polyphenols and neurogenesis: Molecular interactions and implication for brain ageing and cognition
390. Dietary polyphenols and the prevention of diseases
391. Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects
392. Dietary Polyphenols as Modulators of Brain Functions: Biological Actions and Molecular Mechanisms…
393. Dietary polyphenols as potential remedy for dementia
394. Dietary Polyphenols—Important Non-Nutrients in the Prevention of Chronic Noncommunicable Diseases. A Systematic Review
395. Dietary Polyphenols: A Multifactorial Strategy to Target Alzheimer’s Disease
396. Dietary polyphenols: A novel strategy to modulate microbiota-gut-brain axis
397. Dietary Strategies and Supplements for the Prevention of Cognitive Decline and Alzheimer’s Disease
398. Dietary supplementation of walnut partially reverses 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine induced neurodegeneration in a mouse model of Parkinson’s …
399. Dietary supplementation with fruit polyphenolics ameliorates age-related deficits in behavior and neuronal markers of inflammation and oxidative stress
400. Dietary Supplements as Cognitive Enhancers: The Role of Flavonoid-Rich Foods and their Relevance in Age-Related Neurodegeneration
401. Dietary total prenylflavonoids from the fruits of Psoralea corylifolia L. prevents age-related cognitive deficits and down-regulates Alzheimer’s markers in SAMP8 mice
402. Differential oxidative stress in oligodendrocytes and neurons after excitotoxic insults and protection by natural polyphenols
403. Differential Protection among Fractionated Blueberry Polyphenolic Families against DA-, Aβ42- and LPS-Induced Decrements in Ca2+ Buffering in Primary …
404. Direct Evaluation of Alzheimer’s Disease-Specific oxidative stress with Multiphoton Microscopy
405. Discovery development of drugs for alzheimers disease neuroinflammation and elucidating their molecular mechanism of action
406. Discovery of Gut Bacteria Specific to Alzheimer’s Associated Diseases is a Clue to Understanding Disease Etiology: Meta-Analysis of Population-Based Data on …
407. Discovery of Natural Products from Curcuma longa that Protect Cells from Beta-Amyloid Insult: A Drug Discovery Effort against Alzheimer’s Disease
408. Disease contraindication drug use behavior in patients with Parkinson’s disease
409. Disruption of Calcium Homeostasis in Alzheimer’s Disease: Role of Channel Formation by β Amyloid Protein
410. Dissecting molecular mechanisms in the living brain of dementia patients
411. Divergent synthesis of biflavonoids yields novel inhibitors of the aggregation of amyloid β (1–42)
412. Do polyphenols enter the brain and does it matter? Some theoretical and practical considerations
413. Docking of GSK-3β with novel inhibitors, a target protein involved in Alzheimer’s disease
414. Docking study and structure-activity relationships of human glutaminyl cyclase inhibitors for the drug discovery of Alzheimer’s disease
415. Does Parkinson’s disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?
416. Dopamine-Mediated oxidative stress Associated with Neurodegeneration in Parkinson Disease
417. Dopaminergic Neuroprotection with Atremorine in Parkinson´ s Disease
418. Down regulation effect of Rosmarinus officinalis polyphenols on cellular stress proteins in rat pheochromocytoma PC12 cells
419. Down regulation effect of Rosmarinus officinalis polyphenols on cellular stress proteins in rat pheochromocytoma PC12 cells
420. Dracocephalum moldavica L. and Melissa officinalis L.: Chemistry and bioactivities relevant in Alzheimer’s disease therapy
421. Drug delivery systems for resveratrol, a non-flavonoid polyphenol: Emerging evidence in last decades
422. Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer’s disease
423. Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease
424. Dual/multitargeted xanthone derivatives for Alzheimer’s disease: where do we stand?
425. DYRK1A inhibition as potential treatment for Alzheimer’s disease
426. Dysregulation of stress systems and nitric oxide signaling underlies neuronal dysfunction in Alzheimer’s disease
427. Early vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer’s disease
428. Eat to Beat Alzheimer’s
429. EFEITO PROTETOR DO RESVERATROL NA DOENÇA DE ALZHEIMER
430. Effect of Antioxidant Flavanone, Naringenin, from Citrus junos on Neuroprotection
431. Effect of Black Raisins (Vitis vinifera) on Aluminum Chloride Induced Alzheimer’s Disease in Male Albino Rat.
432. Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer’s disease in rats
433. Effect of Chinese herbal medicine on Alzheimer’s disease
434. Effect of dietary supplementation of dates in Alzheimer’s disease APPsw/2576 transgenic mice on oxidative stress and antioxidant status
435. Effect of extraction procedures, genotypes and screening methods to measure the antioxidant potential and phenolic content of orange-fleshed sweetpotatoes …
436. Effect of Imperatorin in Neuropathology of Parkinson’s Disease: An In Silico Study
437. Effect of oil palm phenolics on beta amyloid deposition in cholesterol induced rat model of Alzheimer’s disease: Histological evidence
438. Effect of phenolic-rich plant materials on protein and lipid oxidation reactions
439. Effect of plant extracts on Alzheimer’s disease: An insight into therapeutic avenues
440. Effect of polyphenols on oxidative stress and mitochondrial dysfunction in neuronal death and brain edema in cerebral ischemia
441. Effect of polyphenols on protein misfolding
442. Effects and mechanisms of actions of phytochemicals on Alzheimer’s disease neuropathology
443. Effects and Possible Mechanisms of Some Phytochemicals on Drosophila Models of Alzheimer’s Disease
444. Effects of berry polyphenols on cognitive function in humans
445. Effects of Berry, Pomegranate, Grape and their Biophenols on Cognitive Function: A General Re-view
446. Effects of biflavonoids from Garcinia madruno on a triple transgenic mouse model of Alzheimer’s disease
447. Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia
448. Effects of Dietary Components on Microglia Inactivation in Alzheimer’s Disease
449. Effects of dietary docosahexaenoic acid supplementation on pathology and cognition in a mouse model of Alzheimer’s disease
450. Effects of essential oils and aromatherapy on cognitive function in dementia: laboratory studies and application in aged care facility residents
451. Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia
452. Effects of flavonoids on MMP-13 Expression of IL-1β-treated Articular Chondrocytes and Their Cellular Mechanisms: Inhibition of c-Fos/AP-1 and JAK/STAT …
453. Effects of green tea polyphenol on cognitive and acetylcholinesterase activities
454. Effects of Horticultural Activities and Flower Tea Drinking Based on Reminiscent Storytelling on Demented Elders’ Cognitive and Emotional Functions
455. Effects of huanglian-jie-du-tang and its modified formula on the modulation of amyloid-β precursor protein processing in Alzheimer’s disease models
456. Effects of Isoflavone Extract from Fermented Soybean, Chungkukjang, on Cell Cycle Arrest and Apoptosis of MCF-7 Cells
457. Effects of long-term administration of a cocoa polyphenolic extract (Acticoa powder) on cognitive performances in aged rats
458. Effects of medicinal plants on Alzheimer’s disease and memory deficits
459. Effects of peptides on the structure of lipid bilayers: Implication for its therapeutic effect in Alzheimer’s disease
460. Effects of polyphenols on brain ageing and Alzheimer’s disease: focus on mitochondria
461. Effects of resveratrol and other polyphenols on Sirt1: relevance to brain function during aging
462. Effects of resveratrol and other polyphenols on the most common brain age-related diseases
463. Effects of stilbenoid polyphenols (pterostilbene and gnetol) on cardiomyocyte hypertrophy in vitro and in vivo in spontaneously hypertensive heart failure rats
464. Effects of tea catechins on Alzheimer’s disease: Recent updates and perspectives
465. Effects of the flavonoids, silibinin and catechin, on the motility of extended cooled caprine sperm
466. Effects of various flavonoids on the-synuclein fibrillation process
467. Effects on Cognition of Berry, Pomegranate, Grape and Biophenols: A General Review
468. EFFICACY STUDY OF BRAHMYADI YOGA IN THE MANAGEMENT OF Alzheimer’s DISEASE (SMRITI BHRAMSHA)
469. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease
470. Electroanalysis of α-Synuclein Aggregation Related to Parkinson’s Disease
471. Electrochemical biosensors for the detection and study of α-synuclein related to Parkinson’s disease–A review
472. Emerging role of polyphenolic compounds in the treatment of Neurodegenerative diseases: a review of their intracellular targets
473. Emerging Signal Regulating Potential of Genistein against Alzheimer Disease: A Promising Molecule of Interest
474. Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer’s disease
475. Enhancing human cognition with cocoa flavonoids
476. Enrichment of phenolic antioxidants from cranberry (Vaccinium macrocarpon) to improve biological functionality
477. Epigallocatechin gallate (EGCG) inhibits alpha-synuclein aggregation: a potential agent for Parkinson’s disease
478. Epigallocatechin-3-gallate and related phenol compounds redirect the amyloidogenic aggregation pathway of ataxin-3 towards non-toxic aggregates and prevent …
479. Epigallocatechin-3-gallate, a promising molecule for Parkinson’s disease?
480. Epigenetic drug discovery for Alzheimer’s disease
481. Epigenetic effects of natural polyphenols: A focus on SIRT1‐mediated mechanisms
482. ESPEN guidelines on nutrition in dementia
483. Establishing a Connection between Alzheimer’s Disease and Cellular Energy Transduction
484. Establishment of CD method for studies of amyloid-oligomerization process during Alzheimer disease
485. Estimation of antioxidative properties of the natural polyphenols in the oxidation process of model liposome membranes
486. Estimation of dietary flavonoid intake and major food sources of Korean adults
487. Estrogen, neuroinflammation and neuroprotection in Parkinson’s disease: key role of neuron-glia crosstalk
488. Ethanol extract of Epipremnum aureum leaves attenuate intranigral-rotenone induced Parkinson’s disease in rats
489. Ethnobotanical treatment strategies against Alzheimer’s disease
490. Ethnomedicinal Survey of Plants Used as Remedy for Alzheimer’s Disease in Ebonyi State, Nigeria
491. Ethnopharmacological approaches for dementia therapy and significance of natural products and herbal drugs
492. Eupatilin: a natural pharmacologically active flavone compound with its wide range applications
493. Evaluating the neuroprotective effects of fermented rooibos herbal tea in Wistar rats exposed to bisphenol-A during gestation and lactation
494. Evaluation of anti-oxidant activities and total phenolic content of Chromolaena odorata
495. Evaluation of antioxidant activities and total phenolic content of methanolic extract of Rhodiola heterodanta roots
496. evaluation of antiparkinson activity of hesperetin pyridoxine against olanzepine and manganese induced parkinsonism
497. Evaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer’s disease
498. Evaluation of Memory Enhancing Activity of Methanolic Extract of Oxalis corniculata Linn on dementia in Experimental Animals
499. Evaluation of plant phenolic metabolites as a source of Alzheimer’s drug leads
500. Evaluation of the neuroprotective and antidiabetic potential of phenol-rich extracts from virgin olive oils by in vitro assays
501. Evaluation to the antioxidant activity of total flavonoids extract from persimmon (Diospyros kaki L.) leaves
502. Evidence of neuroprotective effects of saffron and crocin in a Drosophila model of parkinsonism
503. Evidence of oxidative stress in Alzheimer’s disease brain and antioxidant therapy: lights and shadows
504. Evolutionary medicine’perspectives on Alzheimer’s Disease: Review and new directions
505. Exploration of Mitochondrial Dysfunction, Depolarization and Polyphenols by Creative Synthesis for Product Development
506. Exploring the benefits of cellular models to uncover bioactive polyphenols for neurodegeneration
507. Exploring the bioavailability of (poly) phenols from berries and their potential activities in humans
508. Exploring the efficacy of natural products in alleviating Alzheimer’s disease
509. Exploring the mechanism of flavonoids through systematic bioinformatics analysis
510. Exploring the potential of marine microbes in clinical management of Alzheimer’s disease: A road map for bioprospecting and identifying promising isolates
511. Extra-virgin olive oil for potential prevention of Alzheimer disease
512. Extra-virgin olive oil for potential prevention of Alzheimer disease
513. Factors affecting the levels of tea polyphenols and caffeine in tea leaves
514. Fate of microbial metabolites of dietary polyphenols in rats: is the brain their target destination?
515. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer’s disease
516. Ferulic Acid and Alzheimer’s Disease: Promises and Pitfalls
517. Fight Alzheimer’s with Vitamins and Antioxidants
518. Fight Parkinson’s and Huntington’s with Vitamins and Antioxidants
519. First synthesis of the antiangiogenic homoisoflavanone, cremastranone
520. Flavan-3-ol compounds from wine wastes with in vitro and in vivo antioxidant activity
521. Flavanols, mild cognitive impairment, and Alzheimer’s dementia
522. Flavanonol glucosides from the aerial parts of Agrimonia pilosa Ledeb. and their acetylcholinesterase inhibitory effects
523. Flavins and flavoproteins: applications in medicine
524. Flavone: An Important Scaffold for Medicinal Chemistry
525. Flavones from root of Scutellaria baicalensis Georgi: drugs of the future in neurodegeneration?
526. Flavones from the root of Scutellaria baicalensis Georgi—drug of the future in neurodegeneration and neuroprotection
527. Flavones: An important scaffold for medicinal chemistry
528. flavonoid baicalein attenuates activation-induced cell death of brain microglia
529. flavonoid bioactivity: transport across blood-brain-barrier and neuroprotective effects. In vivo studies
530. flavonoid enhances the glyoxalase pathway in cerebellar neurons to retain cellular functions
531. flavonoid hesperidin induces synapse formation and improves memory performance through the astrocytic TGF-β1
532. flavonoid in enhancing memory function
533. flavonoid inhibitors of alpha-synuclein fibrillation: A therapeutic strategy for Parkinson’s disease, and, The effect of membranes on SMA fibrillation
534. flavonoid Intake and Dementia
535. flavonoid intake and disability-adjusted life years due to Alzheimer’s and related dementias: a population-based study involving twenty-three developed countries
536. flavonoid modulation of GABAA receptors
537. flavonoid transport across blood-brain barrier: Implication for their direct neuroprotective actions
538. flavonoid transport across RBE4 cells: a blood-brain barrier model
539. flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia
540. Flavonoid-based therapies in the early management of Neurodegenerative diseases
541. Flavonoid-rich foods (FRF): A promising nutraceutical approach against lifespan-shortening diseases
542. Flavonoidal Compound Derived from Chrysanthemum indicum L. Suppresses MUC5AC Mucin Gene Expression, Production and Secretion from Cultured …
543. Flavonoids
544. flavonoids and Aging
545. flavonoids and anthranquinones as xanthine oxidase and monoamine oxidase inhibitors: a new approach towards inflammation and oxidative stress
546. flavonoids and brain health: multiple effects underpinned by common mechanisms
547. flavonoids and cognition: potential therapeutic role in Alzheimer’s disease
548. flavonoids and cognition: the molecular mechanisms underlying their behavioural effects
549. flavonoids and cognitive function: a review of human randomized controlled trial studies and recommendations for future studies
550. flavonoids and dementia: an update
551. flavonoids and Diarylheptanoids: neuroprotective Activities of Phytochemicals
552. flavonoids and neuroprotection: biochemical and population-based analyses of potential neuroprotective factors related to dementia.
553. flavonoids and Phenolic Acids as Potential Natural Antioxidants
554. flavonoids and the aging brain
555. flavonoids and the brain: Evidences and putative mechanisms for a protective capacity
556. flavonoids and their relation to human health
557. flavonoids as acetylcholinesterase inhibitors: Current therapeutic standing and future prospects
558. flavonoids as detoxifying and pro-survival agents: What’s new?
559. flavonoids as modulators of memory and learning: molecular interactions resulting in behavioural effects
560. flavonoids as neuroprotective and therapeutic agents against aging related neurological disorders
561. flavonoids as novel neuroprotective nutraceuticals
562. flavonoids as prospective neuroprotectants and their therapeutic propensity in aging associated neurological disorders
563. flavonoids as regulators of amyloid precursor protein processing
564. flavonoids as therapeutic agents in Alzheimer’s and Parkinson’s diseases: a systematic review of preclinical evidences
565. flavonoids in Foods and Their Role in Healthy Nutrition
566. flavonoids in human health: from structure to biological activity
567. flavonoids in neurodegeneration: Limitations and strategies to cross CNS barriers
568. flavonoids in the treatment of Alzheimer’s and other Neurodegenerative diseases
569. flavonoids in Transgenic Alzheimer’s Disease Mouse Models
570. flavonoids in Transgenic Alzheimer’s Disease Mouse Models
571. flavonoids inhibit heparin-induced aggregation of the third repeat (r3) of microtubule-binding domain of Alzheimer’s tau protein
572. flavonoids possess neuroprotective effects on cultured pheochromocytoma PC12 cells: a comparison of different flavonoids in activating estrogenic effect and in …
573. flavonoids with Novel Nicotinic Activity as Potential Pharmacotherapies to Treat Ethanol-Induced Neurotoxicity
574. Flavonoids-food sources and health benefits
575. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease
576. Flavonoids: an overview
577. Flavonoids: Broad Spectrum Agents on Chronic Inflammation
578. Flavonoids: important biocompounds in food
579. Flavonoids: its working mechanism and various protective roles
580. Flavonoids: modulators of brain function?
581. Flavonol Glycosides and Phenolic Compounds from Euphorbia maculata
582. Flavonol-rich dark cocoa significantly decreases plasma endothelin-1 and improves cognition in urban children
583. Food antioxidants and Alzheimer’s disease
584. Food, polyphenols and neuroprotection
585. Forestalling the Epidemics of Parkinson’s Disease Through Plant-Based Remedies
586. Formation of the 42-mer Amyloid 𝜷 Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer’s Disease
587. Formulation development and optimization of novel drug delivery systems for the treatment of alzheimers disease
588. Free radical scavenging activity and qualitative analysis of polyphenols by RP-HPLC in the flowers of Couroupita guianensis Abul.
589. Free radical–mediated damage to brain in Alzheimer’s disease: role of acrolein and preclinical promise of antioxidant polyphenols
590. Free radicals and polyphenols: The redox chemistry of Neurodegenerative diseases
591. From the baker to the bedside: yeast models of Parkinson’s disease
592. Fruit and vegetable intake and its association with dementia in the English Longitudinal Study of Ageing
593. Fruit polyphenols and their effects on neuronal signaling and behavior in senescence
594. Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer’s disease
595. Functions of flavonoids in the central nervous system: astrocytes as targets for natural compounds
596. Future Therapeutic Perspectives into the Alzheimer’s Disease Targeting the oxidative stress Hypothesis
597. Gallotannins and Tannic Acid: First Chemical Syntheses and In Vitro Inhibitory Activity on Alzheimer’s Amyloid β‐Peptide Aggregation
598. Gene-environment interaction research and transgenic mouse models of Alzheimer’s disease
599. GENERAL PRACTITIONER’S APPROACH TO DIAGNOSIS, DISCLOSURE AND MANAGEMENT OF dementia IN THE
600. Genetics of iron regulation and the possible role of iron in Parkinson’s disease
601. Genistein ameliorates learning and memory deficits in amyloid β (1–40) rat model of Alzheimer’s disease
602. Ginger components as anti-Alzheimer drugs: focus on drug design
603. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo‐controlled double‐blind study
604. Ginkgo biloba as an alternative medicine in the treatment of anxiety in dementia and other psychiatric disorders
605. Ginkgo biloba extract in Alzheimer’s disease: from action mechanisms to medical practice
606. Gold Nanoparticles and Peptoids as Novel Inhibitors of Amyloid Beta Aggregation in Alzheimer’s Disease
607. Gold nanoparticles and peptoids as novel inhibitors of Aβ aggregation in Alzheimer’s disease
608. Gold Nanoparticles in Diagnosis and Treatment of Alzheimer’s Disease
609. Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer’s disease
610. Green Tea confers Protection on the Retina in MPTP Mice Model of Parkinson’s Disease
611. Green tea intake and risks for dementia, Alzheimer’s disease, mild cognitive impairment, and cognitive impairment: A systematic review
612. Green tea polyphenol (–)‐epigallocatechin‐3‐gallate induces neurorescue of long‐term serum‐deprived PC12 cells and promotes neurite outgrowth
613. Green tea polyphenol (–)‐epigallocatechin‐3‐gallate prevents N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurodegeneration
614. Green tea polyphenol (–)‐epigallocatechin‐3‐gallate promotes the rapid protein kinase C‐and proteasome‐mediated degradation of Bad: implications for …
615. Green tea polyphenols enhance sodium nitroprusside‐induced neurotoxicity in human neuroblastoma SH‐SY5Y cells
616. Green tea polyphenols prevent Parkinson’s disease: in vitro and in vivo studies
617. GRP78/BIP/HSPA5 as a Therapeutic Target in Models of Parkinson’s Disease: A Mini Review
618. Gut microbiota mediated allostasis prevents stress-induced neuroinflammatory risk factors of Alzheimer’s disease.
619. Gut microbiota, cognitive frailty and dementia in older individuals: a systematic review
620. Health benefits of nongallated and gallated flavan-3-ols: a prospectus
621. Health effects of foods rich in polyphenols
622. Healthy Eating to Reduce the Risk of Dementia
623. Hepatoprotective effects of apple polyphenol extract on aluminum-induced liver oxidative stress in the rat
624. Herbal treatment of Parkinsonism: a review
625. Herbs and dementia: a focus on Chinese and other traditional herbs
626. Herbs and Nutrients for Neurologic Disorders: Treatment Strategies for Alzheimer’s, Parkinson’s, Stroke, Multiple Sclerosis, Migraine, and Seizures
627. Hesperetin, a citrus flavonoid, attenuates LPS-induced neuroinflammation, apoptosis and memory impairments by modulating TLR4/NF-κB signaling
628. Hesperidin, a citrus flavonoid, protects against l-methionine-induced hyperhomocysteinemia by abrogation of oxidative stress, endothelial dysfunction and …
629. Heterogeneity in gut microbiota drive polyphenol metabolism that influences α-synuclein misfolding and toxicity
630. High concentrations of a urinary biomarker of polyphenol intake are associated with decreased mortality in older adults
631. Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents
632. Hippocampal neurogenesis in Alzheimer’s disease: is there a role for dietary modulation?
633. Histological Evidence Of The Effect Of Oil Palm Phenolics In Atherogenic Diet Induced Rat Model Of Alzheimer’s Disease
634. HPLC-DAD fingerprinting analysis, antioxidant activities of Tithonia diversifolia (Hemsl.) A. Gray leaves and its inhibition of key enzymes linked to Alzheimer’s …
635. HPLC-PDA isolation and LC-MS/MS detection of an acetylcholinesterase inhibitory flavonoid from Tephrosia purpurea (L.) Pers. in zebrafish brain
636. Human Tau Isoform Aggregation and Selective Detection of Misfolded Tau from Post-Mortem Alzheimer’s Disease Brains
637. Hypericum perforatum improve memory and learning in Alzheimer’s model:(experimental study in mice)
638. Hypericum perforatum phenolic compounds: protective role in the toxicity induced by heterologous expression of α-synuclein and huntingtin in yeast cells
639. Hyperphosphorylation of Tau Protein in Down’s dementia and Alzheimer’s disease: methylation and implications in prevention and therapy
640. Identification of 5-methoxyflavone as a novel DNA polymerase-beta inhibitor and neuroprotective agent against beta-amyloid toxicity
641. Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer’s disease
642. Identification of polyphenolic compounds and black tea extract as potent inhibitors of lipid membrane destabilization by Aβ 42 aggregates
643. IFN-γ and TNF-α are involved during Alzheimer disease progression and correlate with nitric oxide production: a study in Algerian patients
644. Il trattamento con RSV e l’espressione transgenica di PGC-1α proteggono i neuroni dopaminergici nel modello MPTP murino del morbo di Parkinson.
645. Immuno-modulatory effects of microbial metabolites of flavan-3-ols and dimeric procyanidins
646. Impact of Diet on the Pathogenesis of Alzheimer’s Disease
647. Impact of flavonoids on cellular and molecular mechanisms underlying age-related cognitive decline and neurodegeneration
648. Impact of heat treatment on selected vegetables: bioaccessibility of (poly) phenolic compounds after in vitro gastrointestinal digestion and colonic microbiota …
649. Impact of plant-derived flavonoids on Neurodegenerative diseases
650. Implication of green tea as a possible therapeutic approach for Parkinson disease
651. Implications for Degenerative Disorders: Antioxidative Activity, Total Phenols, Flavonoids, Ascorbic Acid, β-Carotene and β-Tocopherol in Aloe vera
652. Implications of polyphenols on endogenous antioxidant defense systems in human diseases
653. Improved mitochondrial function in brain aging and Alzheimer disease-the new mechanism of action of the old metabolic enhancer piracetam
654. In search of therapeutic solutions for Alzheimer’s disease
655. In silico investigation of the pharmacological mechanisms of beneficial effects of Ginkgo biloba L. on Alzheimer’s Disease
656. In silico studies applied to natural products with potential activity against Alzheimer’s disease
657. In vitro anti-nitrosative, antioxidant, and cytotoxicity activities of plant flavonoids: a comparative study
658. In vitro antioxidant activity and total phenolic content of ethanolic leaf extract of Stevia rebaudiana Bert.
659. In vitro antioxidant, anti-diabetes, anti-dementia, and inflammation inhibitory effect of Trametes pubescens fruiting body extracts
660. In vitro enzyme inhibition potentials and antioxidant activity of synthetic flavone derivatives
661. In vitro evaluation of extracts from Mentha species for potential treatment of Alzheimer’s disease
662. In vitro peroxynitrite scavenging activity of 6-hydroxykynurenic acid and other flavonoids fromGingko biloba yellow leaves
663. In vivo antioxidant activity of total flavonoids from indocalamus leaves in aging mice caused by D-galactose
664. In Vivo Characterization of CLR01, an Aggregation and Toxicity Inhibitor, with anAlzheimer’s Disease Focus
665. In Vivo Imaging Agents Based on flavonoids for Amyloid’s Plaques in the Brains of Patients with Alzheimer’s Disease
666. In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: a randomized controlled trial
667. In-depth investigation of the binding of flavonoid taxifolin with bovine hemoglobin at physiological pH: Spectroscopic and molecular docking studies
668. In-Vitro Assessment Of Phenolic, Flavonoid, Flavonolic Contents And Antioxidant Activities Of Plant Pleurotus Ostreatus For Neurodegenerative Disorders
669. In-vitro cholinesterase inhibitory activity of dry fruit extract of Phyllanthus emblica relevant to the treatment of Alzheimer’s disease
670. In-vitro evaluation of acetylcholinesterase inhibition and antioxidant activity of selected Palestinian medicinal plants: Implications for Alzheimer’s disease …
671. In-Vitro Evaluation of Cholinesterase Inhibitory and Antioxidant Activities of Tamarindus indica for the Treatment of Alzheimer’s Disease
672. In-vitro screening of acetylcholinesterase inhibitory activity of extracts from Palestinian indigenous flora in relation to the treatment of Alzheimer’s disease
673. In‐vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer’s disease
674. Indian Herbal Medicines used for Treatment of Dementia: An Overview
675. Indian herbs and their therapeutic potential against Alzheimer’s Disease and other neurological disorders
676. Indoleamine 2, 3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer’s disease hippocampus
677. Induction of neuronal differentiation of murine N2a cells by two polyphenols present in the mediterranean diet mimicking neurotrophins activities: resveratrol and …
678. Inflammaging as a prodrome to Alzheimer’s disease
679. Inflammation in Alzheimer’s Disease, and Prevention with Antioxidants and Phenolic Compounds–What Are the Most Promising Candidates?
680. Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications
681. Inflammation: role in Parkinson’s disease and target for therapy
682. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons: possible relevance to the etiology of Parkinson’s disease
683. INFLUENCE OF EXTRACT AND PHENOL GLYCOSIDES FROM ROSE PETALS ON THE FIBRILS OF AMYLOID PEPTIDE Aβ (1-42). STUDY BY …
684. Influence of hesperidin combined with Sinemet on genetical and biochemical abnormalities in rats suffering from Parkinson’s disease
685. Influence of nitrogen fertilizer micro‐dosing on phenolic content, antioxidant, and anticholinesterase properties of aqueous extracts of three tropical leafy vegetables
686. Influences of Diet, Exercise, and Stress on Hippocampal Health in Depression and Alzheimer’s Disease
687. inhibition and antioxidant activity of selected Palestinian medicinal plants: Implications for Alzheimer’s disease therapy
688. Inhibition and disaggregation of α‐synuclein oligomers by natural polyphenolic compounds
689. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism
690. Inhibition of early upstream events in prodromal Alzheimer’s disease by use of targeted antioxidants
691. Inhibition of Hepatic Insulin Resistance by Licorice flavonoids as Mediated by PTP1B Repression
692. Inhibition of Rat Prostate Testosterone 5α-Reductase Activity by Isoflavonoids
693. Inhibition of α-Synuclein contributes to the ameliorative effects of dietary flavonoids luteolin on arsenite-induced apoptotic cell death in the dopaminergic PC12 cells
694. Inhibitory Effect of a flavonoid Dihydromyricetin against Aβ40 Amyloidogenesis and Its Associated Cytotoxicity
695. Inhibitory Effects of Bombusae concretio Salicea on Neuronal Secretion of Alzheimer’s β-Amyloid Peptides, a Neurodegenerative Peptide
696. Inhibitory Effects of Isoflavonoids on Rat Prostate Testosterone 5α-Reductase
697. Inhibitory Mechanism for Amyloid β42 Aggregation by Catechol-type Flavonoids
698. Inhibitory potential of plant secondary metabolites against Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural …
699. Inhibitory properties of phenolic compounds against enzymes linked with human diseases
700. Insights on Metal Ions and Misfolded Proteins in Alzheimer’s Disease Using flavonoid Derivatives and X-ray Fluorescence Microscopy.
701. Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance
702. Intake of flavonoids and risk of dementia
703. Intake of flavonoids and risk of dementia
704. Interaction between 24‐hydroxycholesterol, oxidative stress, and amyloid‐β in amplifying neuronal damage in Alzheimer’s disease: three partners in crime
705. Interaction between flavonoids and the blood–brain barrier: in vitro studies
706. Interaction of polyphenols with other food components as a means for their neurological health benefits
707. Interaction of α-synuclein with Rhus typhina tannin–Implication for Parkinson’s disease
708. Interplay between Alpha-Synuclein and oxidative stress in Parkinson´ s Disease Cell Models
709. Intranasal therapeutic strategies for management of Alzheimer’s disease
710. Investigating blood plasma levels of cytokines and amyloid-β as potential diagnostic biomarkers for preclinical Alzheimer’s disease
711. Investigating the neuroprotective effect of plant (poly) phenols in models of Parkinson´ s disease
712. Investigation of an Interaction of flavonoids on the Antioxidant Activity of Alpha Tocopherol
713. Investigation of anti-inflammatory compounds from food and plant libraries for use in Alzheimer’s disease
714. Investigation of in-vitro antioxidant potential in crotalaria verrucosa along with identification and quantification of its polyphenolic compounds
715. Investigational α-synuclein aggregation inhibitors: hope for Parkinson’s disease
716. Investigations of anticholinestrase and antioxidant potentials of methanolic extract, subsequent fractions, crude saponins and flavonoids isolated from Isodon …
717. Involvement of astrocytes in Alzheimer’s disease from a neuroinflammatory and oxidative stress perspective
718. Iridoid Glycosides and Phenolic Glycosides from Buddleja asiatica with Anti-inflammatory and Cytoprotective Activities
719. Iridoids and other monoterpenes in the Alzheimer’s brain: Recent development and future prospects
720. Iron as a therapeutic target for Parkinson’s disease
721. Iron dysregulation in Alzheimer’s disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein …
722. Is pharmacological prevention of Alzheimer’s a realistic goal?
723. Isoflavones and Alzheimer’s disease: the effects of soy in diet
724. Isolation of eupatorin (3′,5-dihydroxy-4′,6,7-trimethoxyflavone) from Albizia odoratissima and its application for l-tryptophan sensing
725. Isolation of flavonoides from Artemisia macrocephala anticholinesterase activity: Isolation, characterization and its in vitro anticholinesterse activity supported by …
726. Isolation, synthesis, and metabolism of polyphenols: Stilbenoids, gallotannins and ellagitannins
727. Kaempferol attenuates cognitive deficit via regulating oxidative stress and neuroinflammation in an ovariectomized rat model of sporadic dementia
728. Lamiaceae family plants as a potential anticholinesterase source in the treatment of Alzheimer’s disease
729. Lamiaceae phenols as multifaceted compounds: bioactivity, industrial prospects and role of “positive-stress”
730. Lavandula stoechas (L) a Very Potent Antioxidant Attenuates dementia in Scopolamine Induced Memory Deficit Mice
731. Liberation of copper from amyloid plaques: making a risk factor useful for Alzheimer’s disease treatment
732. Lifestyle modifications and nutritional interventions in aging-associated cognitive decline and Alzheimer’s disease
733. Lifestyle patterns as a modifiable risk factor for late-life cognitive decline: A narrative review regarding dementia prevention
734. Lifestyle-related factors in predementia and dementia syndromes
735. Links between insulin resistance, lipoprotein metabolism and amyloidosis in Alzheimer’s Disease
736. Lipid Peroxidation and Mitochondrial Dysfunction in Alzheimer’s and Parkinson’s Diseases: Role of Natural Products as Cytoprotective Agents
737. Liposomal flavonoid in Combating Age-Related Cerebral Oxidative Damage
738. Literature Evidence and ARRIVE Assessment on neuroprotective Effects of Flavonols in Neurodegenerative Diseases’ Models
739. Literature Evidence and Arrive Assessment on neuroprotective Effects of Flavonols Quercetin, Rutin and Isoquercitrin in Neurodegenerative Diseases’ Models
740. Literature-related discovery: common factors for Parkinson’s disease and Crohn’s disease
741. Literature-related discovery: common factors for Parkinson’s Disease and Crohn’s Disease
742. Long-term dietary supplementation of pomegranates, figs and dates alleviate neuroinflammation in a transgenic mouse model of Alzheimer’s disease
743. Long-term naringin consumption reverses a glucose uptake defect and improves cognitive deficits in a mouse model of Alzheimer’s disease
744. Low Phytanic Acid-Concentrated DHA Prevents Cognitive Deficit and Regulates Alzheimer Disease Mediators in an ApoE−/− Mice Experimental Model
745. Low-Molecular Weight Metabolites from Polyphenols as Effectors for Attenuating Neuroinflammation
746. Macroalgae as a Valuable Source of Naturally Occurring Bioactive Compounds for the Treatment of Alzheimer’s Disease
747. Macronutrients, aluminium from drinking water and foods, and other metals in cognitive decline and dementia
748. Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent
749. Management of cognitive determinants in senile dementia of Alzheimer’s type: therapeutic potential of a novel polyherbal drug product
750. Management of oxidative stress and other pathologies in Alzheimer’s disease
751. Mangiferin: a multipotent natural product preventing neurodegeneration in Alzheimer’s and Parkinson’s disease models
752. Mannosylated liposomal flavonoid in combating age-related ischemia–reperfusion induced oxidative damage in rat brain
753. MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide
754. Mechanism involved in insulin resistance via accumulation of β-amyloid and neurofibrillary tangles: link between type 2 diabetes and Alzheimer’s disease
755. Mechanisms of aging and potential role of selected polyphenols in extending healthspan
756. Mechanisms of dietary flavonoid action in neuronal function and neuroinflammation
757. Mechanisms of neuroprotection by polyphenols
758. Mechanistic description of natural herbs in the treatment of dementia: A systematic review
759. Medical management of Parkinson’s disease: focus on neuroprotection
760. Medicinal chemistry approaches for the treatment and prevention of Alzheimer’s disease
761. Medicinal plants and Alzheimer’s disease: Integrating ethnobotanical and contemporary scientific evidence
762. Medicinal plants and dementia therapy: herbal hopes for brain aging?
763. Medicinal plants as protective strategies against Parkinson’s disease
764. Medicinal plants from northeastern Brazil against Alzheimer’s disease
765. Medicinal Plants from Northeastern Brazil against Alzheimer’s Disease
766. Medicinal plants of Brazil and Alzheimer’s disease: Evolution in traditional use and pre-clinical studies
767. Medicinal Plants with Acetylcholinesterase Inhibitory Activity: Therapeutic Potential of Brazilian Plants for the Treatment of Alzheimer’s Disease
768. Medicinal Plants, Phytochemicals and Alzheimer’s
769. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and …
770. Mediterranean and MIND diets containing olive biophenols reduces the prevalence of Alzheimer’s disease
771. Mediterranean diet and risk for Alzheimer’s disease
772. Mediterranean Diet as a Potential Strategy to Reduce Cognitive Decline and dementia in Elderly
773. Mediterranean diet in predementia and dementia syndromes
774. Mediterranean diet, cognitive function, and dementia: a systematic review
775. Mediterranean diet: The role of long-chain ω-3 fatty acids in fish; polyphenols in fruits, vegetables, cereals, coffee, tea, cacao and wine; probiotics and vitamins …
776. Memory-enhancing activities of the aqueous extract of Albizia adianthifolia leaves in the 6-hydroxydopamine-lesion rodent model of Parkinson’s disease
777. Metabolic and immune risk factors for dementia and their modification by flavonoids: New targets for the prevention of cognitive impairment?
778. Metabolic links between diabetes and Alzheimer’s disease
779. Metabolic syndrome and the role of dietary lifestyles in Alzheimer’s disease
780. Metabolomics analysis of Xanthoceras sorbifolia husks protection of rats against Alzheimer’s disease using liquid chromatography mass spectrometry
781. Metal Binding of flavonoids and Their Distinct Inhibition Mechanisms Toward the Oxidation Activity of Cu2+–β-Amyloid: Not Just Serving as Suicide Antioxidants!
782. Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or …
783. Metal chelation, radical scavenging and inhibition of Aβ42 fibrillation by food constituents in relation to Alzheimer’s disease
784. Metal dyshomeostasis and inflammation in Alzheimer’s and Parkinson’s diseases: possible impact of environmental exposures
785. Metal dysregulation in the pathogenesis of Alzheimers disease An experimental study in rat brain and cultured neuroblastoma cells
786. Metal ions and metal complexes in Alzheimer’s disease
787. Metals and amyloid‐β in Alzheimer’s disease
788. Methanolic extract of Hibiscus asper leaves improves spatial memory deficits in the 6-hydroxydopamine-lesion rodent model of Parkinson’s disease
789. Methylglyoxal, glyoxal, and their detoxification in Alzheimer’s disease
790. MICE MODEL OF Parkinson’s DISEASE
791. Microwave assisted extraction of flavonoids from cultivated Epimedium sagittatum: Extraction yield and mechanism, antioxidant activity and chemical composition
792. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study
793. MIND food and speed of processing training in older adults with low education, the MINDSpeed Alzheimer’s disease prevention pilot trial
794. Mitigating Alzheimer’s disease with natural polyphenols: a review
795. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer’s disease
796. Mitochondria as potential targets in Alzheimer disease therapy: An update
797. Mitochondria as targets for neuronal protection against excitotoxicity: a role for phenolic compounds?
798. Mitochondria in neuroprotection by phytochemicals: bioactive polyphenols modulate mitochondrial apoptosis system, function and structure
799. Mitochondria-targeted protective compounds in Parkinson’s and Alzheimer’s diseases
800. Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease
801. Mitochondrial cascade hypothesis of Alzheimer’s disease: myth or reality?
802. Mitochondrial Dysfunction and Alpha-Lipoic Acid: Beneficial or Harmful in Alzheimer’s Disease?
803. Mitochondrial dysfunction in Parkinson’s disease: pathogenesis and neuroprotection
804. Mitochondrial dysfunction—a pharmacological target in Alzheimer’s disease
805. Mitochondrial dysfunction: cause and consequence of Alzheimer’s
806. Mitochondrial dysfunction: cause and consequence of Alzheimer’s disease
807. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer’s disease—therapeutic aspects
808. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer’s disease?
809. Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols
810. Mitochondrial Therapeutic Approaches in Parkinson’s Disease
811. Moderate consumption of Cabernet Sauvignon attenuates Aβ neuropathology in a mouse model of Alzheimer’s disease
812. Modulating Effect of Diet on Alzheimer’s Disease
813. Modulation of Alzheimer-like Pathology in Type 2 Diabetic Rats via Grape Seed or Ginseng Extracts
814. Modulation of endogenous antioxidant system by wine polyphenols in human disease
815. Modulation of mitochondrial calcium as a pharmacological target for Alzheimer’s disease
816. Modulation of multiple neuroinflammatory signalling pathways by the dietary glycosidic flavonoid tiliroside
817. MODULATION OF NEUROINFLAMMATION BY MEDICINAL HERBS AND FLAVONOIDS
818. Modulation of Nrf2 by olive oil and wine polyphenols and neuroprotection
819. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and Neurodegenerative disorders
820. Modulation of Pro-inflammatory Mediators by Eugenol in AlCl3 Induced dementia in Rats
821. Molecular characterization of multi-targets by bis (7)-tacrineat amyloid β cascade associated with Alzheimer’s disease
822. Molecular Mechanism of the Inhibition of EGCG on the Alzheimer Aβ1–42 Dimer
823. Molecular mechanisms of the neuroprotective/neurorescue action of multi-target green tea polyphenols
824. Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer’s disease
825. Molecular mechanisms underlying the flavonoid-induced inhibition of α-synuclein fibrillation
826. Molecular pathology and pharmacogenomics in Alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression
827. Molecular pharmacology of rosmarinic and salvianolic acids: Potential seeds for Alzheimer’s and vascular dementia drugs
828. Molecular study of cell culture models of Parkinson’s disease and Huntington’s disease.
829. Molecular targets in Alzheimer’s disease: from pathogenesis to therapeutics
830. Monoamine oxidase and α-synuclein as targets in Parkinson’s disease therapy
831. Monoamine Oxidase B and Free Radical Scavenging Activities of Natural flavonoids in Melastoma candidum D. Don
832. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies
833. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies
834. Mucuna pruriens seeds in treatment of Parkinson’s disease: pharmacological review
835. Mulberry fruit extract protects against memory impairment and hippocampal damage in animal model of vascular dementia
836. Multi-target directed drugs as a modern approach for drug design towards Alzheimer’s disease: an update
837. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer’s disease
838. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer’s disease
839. Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer’s disease
840. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer’s disease drugs
841. Multifunctional neuroprotective–neurorescue drugs for Parkinson’s disease
842. Multiple pharmacological activities of Caesalpinia crista against aluminium-induced neurodegeneration in rats: Relevance for Alzheimer’s disease
843. Multipotent natural agents to combat Alzheimer’s disease. Functional spectrum and structural features1
844. Na+‐K+‐ATPase, a potent neuroprotective modulator against Alzheimer disease
845. Nano-delivery systems for encapsulation of dietary polyphenols: An experimental approach for Neurodegenerative diseases and brain tumors
846. Nano-encapsulation of a natural polyphenol, green tea catechins: way to preserve its antioxidative potential
847. Nanoformulations of polyphenols for prevention and treatment of cardiovascular and metabolic disorders
848. Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer’s Disease
849. Nanoparticle formulations in the diagnosis and therapy of Alzheimer’s disease
850. Nanoparticles as nanocarriers of resveratrol for Alzheimer’s disease
851. Nanotechnology and Alzheimer’s Disease: What has been Done and What to Do’
852. Nanotechnology based Theranostic approaches in Alzheimer’s disease management: current status and future perspective
853. Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds
854. Nanotherapeutic strategies for the treatment of Alzheimer’s disease
855. Nardostacys Jatamansi DC Protects from the loss of memory and cognition deficits in sleep deprived Alzheimer’s disease (Ad) mice model
856. Naringenin ameliorates Alzheimer’s disease (AD)-type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin …
857. Naringin ameliorates memory deficits in experimental paradigm of Alzheimer’s disease by attenuating mitochondrial dysfunction
858. Natural Antioxidants in Dementia: An Overview
859. Natural compounds and plant extracts as therapeutics against chronic inflammation in Alzheimer’s disease–a translational perspective
860. Natural compounds and their derivatives as multifunctional agents for the treatment of alzheimer disease
861. Natural Compounds as Beneficial Antioxidant Agents in Neurodegenerative Disorders: A Focus on Alzheimer’s Disease
862. Natural compounds for Alzheimer’s disease therapy: a systematic review of preclinical and clinical studies
863. Natural Compounds for the Management of Parkinson’s Disease and Attention-Deficit/Hyperactivity Disorder
864. Natural Neuroprotectives for the Management of Parkinson’s Disease
865. Natural phenolic compounds as therapeutic and preventive agents for cerebral amyloidosis
866. Natural phytochemicals in the treatment and prevention of dementia: An overview
867. Natural Phytoestrogens: A Class of Promising neuroprotective Agents for Parkinson Disease
868. Natural plant-derived acetylcholinesterase inhibitors: Relevance for Alzheimer’s disease
869. Natural polyphenols against Neurodegenerative disorders: potentials and pitfalls
870. Natural polyphenols binding to amyloid: A broad class of compounds to treat different human amyloid diseases
871. Natural polyphenols effects on protein aggregates in Alzheimer’s and Parkinson’s prion-like diseases
872. Natural polyphenols in the treatment of Alzheimer’s disease
873. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation
874. Natural Product Chemical Probe Discovery against Parkinson’s Disease
875. Natural product formulations for the prevention and treatment of Alzheimer’s disease: a patent review
876. Natural product polyphenols of relevance to human health
877. Natural products against Alzheimer’s disease: Pharmaco-therapeutics and biotechnological interventions
878. Natural products and derivatives affecting neurotransmission relevant to Alzheimer’s and Parkinson’s disease
879. Natural products and their derivatives as multifunctional ligands against Alzheimer’s disease
880. Natural products as a source of Alzheimer’s drug leads
881. Natural products as promising drug candidates for the treatment of Alzheimer’s disease: molecular mechanism aspect
882. Natural products combating neurodegeneration: Parkinson’s disease
883. Natural Products for the Treatment of Alzheimer’s Disease: Present and Future Expectations
884. Natural Products for Treatment of Alzheimer’s Disease
885. Natural products in Alzheimer’s disease therapy: would old therapeutic approaches fix the broken promise of modern medicines?
886. Natural Products-Based Drugs: Potential Therapeutics against Alzheimer’s Disease and other Neurological Disorders
887. Natural stilbenes effects in animal models of Alzheimer’s disease
888. Natural Therapeutics for Alzheimer’s Disease
889. Naturally Inspired Privileged Structures in Drug Discovery: Multifunctional Compounds for Alzheimer’s Disease Treatment
890. Nature as a source of metabolites with cholinesterase‐inhibitory activity: an approach to Alzheimer’s disease treatment
891. neuro Protective Role of Selected medicinal Plant In Alzheimers Disease Design of Novel Drugs
892. Neuro-nutrients as anti-Alzheimer’s disease agents: A critical review
893. Neurobiological aspects of Alzheimer’s disease
894. Neurobiological effects of Hyperforin and its potential in Alzheimer’s disease therapy
895. Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits
896. Neurocognitive improvement through plant food bioactives: A particular approach to Alzheimer’s disease
897. Neurodegenerative diseases: might citrus flavonoids play a protective role?
898. Neurogenesis and neuroprotection in postischemic brain neurodegeneration with Alzheimer phenotype: is there a role for curcumin
899. Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer’s disease
900. Neurogenic traditional Chinese medicine as a promising strategy for the treatment of Alzheimer’s disease
901. Neuroinflammation in Alzheimer’s disease: the preventive and therapeutic potential of polyphenolic nutraceuticals
902. Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention
903. Neuroinflammatory processes in cognitive disorders: Is there a role for flavonoids and n-3 polyunsaturated fatty acids in counteracting their detrimental effects?
904. Neurological mechanisms of green tea polyphenols in Alzheimer’s and Parkinson’s diseases
905. Neuronal death in Alzheimer’s disease and therapeutic opportunities
906. Neuronutrition and Alzheimer’s disease
907. Neuropharmacological Activity of Apium graveolens L. and its neuroprotective Effect on MPTP-Induced Parkinson-Like Symptoms
908. Neuropharmacological properties and pharmacokinetics of the citrus flavonoids hesperidin and hesperetin—a mini-review
909. Neuroprotection by natural polyphenols: molecular mechanisms
910. Neuroprotection in Alzheimer Disease
911. Neuroprotection of brain-targeted bioactive dietary artoindonesianin O (AIO) from mulberry on rat neurons as a novel intervention for Alzheimer’s disease
912. Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway
913. neuroprotective actions of flavones and flavonols: mechanisms and relationship to flavonoid structural features
914. neuroprotective actions of flavonoids
915. neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice
916. neuroprotective attributes of L-theanine, a bioactive amino acid of tea, and its potential role in Parkinson’s disease therapeutics
917. neuroprotective effect and antioxidant activity of Passiflora edulis fruit flavonoid fraction, aqueous extract, and juice in aluminum chloride-induced Alzheimer’s …
918. neuroprotective effect of blackberry (Rubus sp.) polyphenols is potentiated after simulated gastrointestinal digestion
919. neuroprotective effect of brassica oleracea sprouts crude juice in a cellular model of Alzheimer’s disease
920. neuroprotective effect of cocoa flavonids on in vitro oxidative stress
921. neuroprotective effect of EGb761® and low-dose whole-body γ-irradiation in a rat model of Parkinson’s disease
922. neuroprotective effect of ellagic acid against chronically scopolamine induced Alzheimer’s type memory and cognitive dysfunctions: possible behavioural and …
923. neuroprotective effect of flavonoids via up-regulation of Nrf2-ARE pathway, in MPP+-induced PC12 cells
924. neuroprotective Effect of Flavonoids: A Systematic Review
925. neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson’s disease
926. neuroprotective effect of hesperetin and nano-hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of Alzheimer’s …
927. neuroprotective effect of hesperidin on aluminium chloride induced Alzheimer’s disease in Wistar rats
928. neuroprotective effect of naringin, a dietary flavonoid against 3-nitropropionic acid-induced neuronal apoptosis
929. neuroprotective effect of natural products against Alzheimer’s disease
930. neuroprotective effect of olive oil polyphenols in Alzheimer’s disease
931. neuroprotective effect of phytic acid in Parkinson’s disease
932. neuroprotective effects associated with wine and its phenolic constituents
933. neuroprotective effects of amantadine–flavonoid conjugates
934. neuroprotective effects of citrus Fruit-Derived flavonoids, nobiletin and Tangeretin in Alzheimer’s and Parkinson’s Disease
935. neuroprotective effects of digested polyphenols from wild blackberry species
936. neuroprotective effects of epigallocatechin gallate in cell culture and animal models of Parkinson’s disease
937. neuroprotective effects of fisetin in Alzheimer’s and Parkinson’s Diseases: From chemistry to medicine
938. neuroprotective effects of naturally occurring polyphenols on quinolinic acid‐induced excitotoxicity in human neurons
939. neuroprotective effects of phenolic and carboxylic acids on oxidative stress-induced toxicity in human neuroblastoma SH-SY5Y cells
940. neuroprotective Effects of Polyphenols
941. neuroprotective Effects of Polyphenols in Aging and Age‐Related Neurological Disorders
942. neuroprotective Effects of Quercetin in Alzheimer’s Disease
943. neuroprotective effects of resveratrol and epigallocatechin gallate polyphenols are mediated by the activation of protein kinase C gamma
944. neuroprotective effects of resveratrol in Alzheimer disease pathology
945. neuroprotective effects of rutin and quercetin flavonoids in glaucium corniculatum methanol and water extracts
946. neuroprotective effects of selected microbial-derived phenolic metabolites and aroma compounds from wine in human sh-sy5y neuroblastoma cells and their …
947. neuroprotective mechanisms of resveratrol in Alzheimer’s disease: role of SIRT1
948. neuroprotective natural products for the treatment of Parkinson’s disease by targeting the autophagy–lysosome pathway: A systematic review
949. neuroprotective potential of withania somnifera in rotenone induced parkinsonism in mice
950. neuroprotective properties of a standardized extract from Myracrodruon urundeuva Fr. All.(Aroeira-Do-Sertao), as evaluated by a Parkinson’s disease model in rats
951. neuroprotective properties of dietary polyphenols in Parkinson’s disease
952. neuroprotective Properties of Partridgeberry (Vaccinium vitis-idaea L. var. minus Lodd) Polyphenols
953. neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson’s disease
954. neuroprotective role of antioxidant and pyranocarboxylic acid derivative against AlCl3 induced Alzheimer’s disease in rats
955. neuroprotective Role of Green Tea Polyphenols on the Superior Colliculus in MPTP Mice Model of Parkinson’s Disease
956. neuroprotective role of natural polyphenols
957. neuroprotective strategies in Parkinson’s disease
958. neuroprotective Strategies in Parkinson’s Disease Using the Models of 6‐Hydroxydopamine and MPTPa
959. neuroprotective Strategies in Parkinson’s Disease Using the Models of 6‐Hydroxydopamine and MPTPa
960. neuroprotective strategies to prevent and treat Parkinson’s disease based on its pathophysiological mechanism
961. neuroprotective therapies for Alzheimer’s disease
962. Neurosupportive role of vanillin, a natural phenolic compound, on rotenone induced neurotoxicity in SH-SY5Y neuroblastoma cells
963. Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
964. New acetylcholinesterase inhibitors for Alzheimer’s disease
965. New methodology for the biomimetic synthesis of Flavan-3, 4-diols and derivatives
966. NF-κB-Mediated Neuroinflammation in Parkinson’s Disease and Potential Therapeutic Effect of Polyphenols
967. Nitric oxide mediates neurovascular coupling in the brain effect of polyphenols in animal models of Alzheimer’s disease
968. Nonpeptide neurotrophic agents useful in the treatment of Neurodegenerative diseases such as Alzheimer’s disease
969. Nonpharmacological Modulation of Chronic Inflammation in Parkinson’s Disease: Role of Diet Interventions
970. Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease
971. Nootropic and anti-Alzheimer’s actions of medicinal plants: molecular insight into therapeutic potential to alleviate Alzheimer’s neuropathology
972. Nootropic Medicinal Plants: Therapeutic Alternatives for Alzheimer’s disease
973. Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer’s disease treatment
974. Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer’s therapy
975. Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
976. Novel Mannitol-Based Small Molecules for Inhibiting Aggregation of α-Synuclein Amyloids in Parkinson’s Disease
977. Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties
978. Novel neuroprotective Therapies for Alzheimer’s and Parkinsons’s Disease
979. Novel photoaffinity probes of homoisoflavonoids for target identification of retinal neovascularization
980. Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease
981. Novel regimen through combination of memantine and tea polyphenol for neuroprotection against brain excitotoxicity
982. Novel tacrine-scutellarin hybrids as multipotent anti-Alzheimer’s agents: Design, synthesis and biological evaluation
983. Novel tactics for neuroprotection in Parkinson’s disease: role of antibiotics, polyphenols and neuropeptides
984. Novel targets for parkinsonism-depression comorbidity
985. Novel therapeutic strategies for dementia
986. Novel Therapeutics in Alzheimer’s Disease
987. Nutraceutical potential of phenolics from′ brava′ and′ mansa′ extra-virgin olive oils on the inhibition of enzymes associated to Neurodegenerative disorders in …
988. Nutraceutical Potential of Phenolics fromBrava´ andMansa´ Extra-Virgin Olive Oils on the Inhibition of Enzymes Associated to Neurodegenerative Disorders in …
989. Nutraceuticals and amyloid Neurodegenerative diseases: a focus on natural phenols
990. Nutraceuticals and their preventive or potential therapeutic value in Parkinson’s disease
991. Nutraceuticals in cognitive impairment and Alzheimer’s
992. Nutraceuticals in cognitive impairment and Alzheimer’s disease
993. Nutraceuticals in the Prevention or Treatment of Parkinson’s Disease
994. Nutraceuticals Neuroprotect Naturally: Alzheimer’s disease, Parkinson’s disease, Stroke and Major Depressive Disorder
995. Nutraceuticals: a novel concept in prevention and treatment of Alzheimer’s disease and related disorders
996. Nutraceuticals: an emerging therapeutic approach against the pathogenesis of Alzheimer’s disease
997. Nutraceuticals: dietary flavonoids
998. Nutrients in the Prevention of Alzheimer’s Disease
999. Nutrition and AGE-ing: Focusing on Alzheimer’s Disease
1000. Nutrition and the risk for Parkinson’s disease: review of the literature
1001. Nutrition and the risk of Alzheimer’s disease
1002. Nutrition increases Survival and Reverses NAFLD and Alzheimer’s disease
1003. Nutrition Society Silver Medal Lecture Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain
1004. Nutrition: Review on the possible treatment for Alzheimer’s disease
1005. Nutritional and pharmacological strategies to regulate microglial polarization in cognitive aging and Alzheimer’s disease
1006. Nutritional approaches to combat oxidative stress in Alzheimer’s disease
1007. Nutritional approaches to modulate oxidative stress in Alzheimer’s disease
1008. Nutritional contributions to dementia prevention: main issues on antioxidant micronutrients
1009. Nutritional habits, risk, and progression of Parkinson disease
1010. Nutritional prevention of cognitive decline and dementia
1011. O-Methylated flavonoid Isorhamnetin Protects against oxidative stress via Activation of Nrf2 and Target Gene Expression
1012. Oil palm phenolics inhibit the in vitro aggregation of β-amyloid peptide into oligomeric complexes
1013. Old age-associated phenotypic screening for Alzheimer’s disease drug candidates identifies sterubin as a potent neuroprotective compound from Yerba santa
1014. Olive biophenols reduces Alzheimer’s pathology in SH-SY5Y cells and APPswe mice
1015. Olive polyphenols: New promising agents to combat aging-associated neurodegeneration
1016. Omics and Epigenetics of Polyphenol-Mediated Neuroprotection: The Curcumin Perspective
1017. On the role of synthesized hydroxylated chalcones as dual functional amyloid-β aggregation and ferroptosis inhibitors for potential treatment of Alzheimer’s disease
1018. ON THE THERAPEUTIC PROPERTIES OF NATURALLY OCCURRING FLAVONOID-QUERCETIN: A MAGICAL THERAPEUTIC AGENT
1019. One‐compound‐multiple‐targets strategy to combat Alzheimer’s disease
1020. Original Research Phenolics, antioxidant and anti-inflammatory activities of Melia azedarachextracts
1021. Orobol: An Isoflavone Exhibiting Regulatory Multifunctionality against Four Pathological Features of Alzheimer’s Disease
1022. Orthosiphon stamineus improves memory in scopolamine-induced amnesia model of cholinergic hypothesis of Alzheimer’s disease
1023. Outsmarting Alzheimer’s: What You Can Do to Reduce Your Risk
1024. Overview of Alzheimer’s disease and some therapeutic approaches targeting Aβ by using several synthetic and herbal compounds
1025. Overviews of biological importance of quercetin: A bioactive flavonoid
1026. Oxidant/antioxidant imbalance and the risk of Alzheimer’s disease
1027. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8‐hydroxyguanine levels in substantia nigra
1028. Oxidative modification of vesicular transporters in an animal model of Alzheimer’s disease
1029. oxidative stress and Alzheimer’s disease: dietary polyphenols as potential therapeutic agents
1030. oxidative stress and amyloid beta toxicity in Alzheimer’s disease: intervention in a complex relationship by antioxidants
1031. oxidative stress and inflammation: what polyphenols can do for us?
1032. oxidative stress and neuroinflammation in Alzheimer’s disease and amyotrophic lateral sclerosis: From biology to therapeutic strategies
1033. oxidative stress events and neuronal dysfunction in Alzheimer’s disease: focus on APE1/Ref-1-mediated survival strategies
1034. oxidative stress in Alzheimer patients in different stages of the disease
1035. oxidative stress in Alzheimer’s Disease: A Review on Emergent Natural Polyphenolic Therapeutics
1036. oxidative stress in Alzheimer’s disease: implications for prevention and therapy
1037. oxidative stress in Parkinson’s disease
1038. oxidative stress in Parkinson’s disease
1039. oxidative stress in Parkinson’s disease; parallels between current animal models, human studies and cells
1040. Oxidative stress: a bridge between Down’s syndrome and Alzheimer’s disease
1041. Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease
1042. Parkinson’s disease and tea: a quantitative review
1043. Parkinson’s Disease Model in vitro and in C. elegans
1044. Parkinson’s Disease-associated LRRK2 Mutation Causes Abnormal Protein Accumulation-related Cytotoxicity
1045. Parkinson’s disease: from pathogenesis to pharmacogenomics
1046. Parkinson’s disease: the emerging role of gut dysbiosis, antibiotics, probiotics, and fecal microbiota transplantation
1047. Partridgeberry polyphenols protect primary cortical and hippocampal neurons against β-amyloid toxicity
1048. Past and Present Drug Development for Alzheimer’s Disease
1049. Pelargonidin improves memory deficit in amyloid β25-35 rat model of Alzheimer’s disease by inhibition of glial activation, cholinesterase, and oxidative stress
1050. Pelargonidin improves passive avoidance task performance in a rat amyloid beta25-35 model of Alzheimer’s disease via estrogen receptor independent pathways
1051. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer’s disease
1052. Pharmacoepigenomic interventions as novel potential treatments for Alzheimer’s and Parkinson’s diseases
1053. Pharmacogenomics in Alzheimer’s disease
1054. Pharmacogenomics of Alzheimer’s disease: Novel therapeutic strategies for drug development
1055. Pharmacokinetics and Tissue Distribution of 14C-Labeled Grape Polyphenols in the Periphery and the Central Nervous System Following Oral Administration
1056. PHARMACOLOGICAL ACTIVITY OF NATURAL PRODUCTS IN VITRO AND IN ANIMAL MODELS OF Parkinson’s DISEASE AND DEPRESSION
1057. Pharmacological effects of active components of Chinese herbal medicine in the treatment of Alzheimer’s disease: a review
1058. PHARMACOLOGICAL EVALUATION OF TRIPHALA CHURNA INSTREPTOZOTOCIN (ICV) INDUCED dementia IN RATS
1059. Pharmacological Investigation and Unraveling Mechanism of Action ofJasminum sambac Flowers for Predicated Treatment of Alzheimer’s Disease
1060. Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson’s disease
1061. Pharmacological properties and therapeutic potential of naringenin: a citrus flavonoid of pharmaceutical promise
1062. PHARMACOLOGY OF OLIVE BIOPHENOLS IN Alzheimer’s DISEASE PREVENTION AND TREATMENT
1063. Pharmacophore-based drug design of novel potential tau ligands for Alzheimer’s disease treatment
1064. Pharmacotherapies for Alzheimer’s disease: beyond cholinesterase inhibitors
1065. Pharmacotherapies for Alzheimer’s Disease: From Natural Compounds to Target Synthetic Drugs
1066. Phenolic Acid Intake, Delivered Via Moderate Champagne Wine Consumption, Improves Spatial Working Memory Via the Modulation of Hippocampal and Cortical …
1067. Phenolic acids exert anticholinesterase and cognition-improving effects
1068. Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity
1069. Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein
1070. Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein
1071. Phenolic composition, antioxidant and enzyme inhibitory activities of acetone, methanol and water extracts of Clinopodium vulgare L. subsp. vulgare L.
1072. Phenolic compounds and their health benefits: A review
1073. Phenolic compounds characteristic of the mediterranean diet in mitigating microglia-mediated neuroinflammation
1074. Phenolic compounds from edible algae: Bioactivity and health benefits
1075. Phenolic Compounds from the Leaves and Stems of Desmodium Caudatum
1076. Phenolic compounds in fruits and beverages consumed as part of the mediterranean diet: their role in prevention of chronic diseases
1077. Phenolic compounds in fruits and beverages consumed as part of the mediterranean diet: their role in prevention of chronic diseases
1078. Phenolic compounds of green tea: Health benefits and technological application in food
1079. Phenolic compounds prevent Alzheimer’s pathology through different effects on the amyloid-β aggregation pathway
1080. Phenolic compounds prevent the oligomerization of α‐synuclein and reduce synaptic toxicity
1081. Phenolic Compounds with IL-6 Inhibitory Activity from Akebia quinata
1082. Phenolic content of grapevine leaves (Vitis labrusca var. Bordo) and its neuroprotective effect against peroxide damage
1083. Phenolic content, enzyme inhibitory and antioxidative activity potentials of Phlomis nissolii and P. pungens var. pungens
1084. Phenolic contents and bioactive potential of peach fruit extracts
1085. Phenolic contents, antioxidant and anticholinesterase potentials of crude extract, subsequent fractions and crude saponins from Polygonum hydropiper L
1086. Phenolic Extracts from Clerodendrum volubile Leaves Inhibit Cholinergic and Monoaminergic Enzymes Relevant to the Management of Some Neurodegenerative …
1087. Phenolic profile and antioxidative properties of pulp and seeds of Randia monantha Benth
1088. Phenolic profile of three wild edible mushroom extracts from Ordu, Turkey and their antioxidant properties, enzyme inhibitory activities
1089. Phenolic, flavonoid contents, anticholinesterase and antioxidant evaluation of Iris germanica var; florentina
1090. Phenylpropanoids and Alzheimer’s disease: A potential therapeutic platform
1091. Phloretin attenuates behavior deficits and neuroinflammatory response in MPTP induced Parkinson’s disease in mice
1092. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer’s disease
1093. Phosphorylation and sequence dependency of neurofilament protein oxidative modification in Alzheimer disease
1094. Phyto‐Tacrine Hybrids as Promising Drugs to Treat Alzheimer’s Disease
1095. Phytochemical and pharmacological properties of flavonols
1096. Phytochemical Evaluation of Lagerstroemia indica (L.) Pers. Leaves as Anti-Alzheimer’s
1097. Phytochemicals and cognitive health: Are flavonoids doing the trick?
1098. Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease
1099. Phytochemicals Bridging Autophagy Induction and Alpha-Synuclein Degradation in Parkinsonism
1100. Phytochemicals, Antioxidants, and Cholinesterase Inhibitory Profiles of Elatostema Papillosum Leaves: An Alternative Approach for Management of Alzheimer’s …
1101. Pinus halepensis essential oil attenuates the toxic Alzheimer’s amyloid beta (1-42)-induced memory impairment and oxidative stress in the rat hippocampus
1102. PLANT BASED INDIAN TRADITIONAL MEDICINE FOR Neurodegenerative DISEASES-A NOVEL APPROACH TO TREAT ALZHEIMER
1103. Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson’s Disease Models
1104. Plant phenolics affect oxidation of tryptophan
1105. Plant phenolics as functional food ingredients
1106. Plant polyphenols as dietary antioxidants in human health and disease
1107. Plant polyphenols as dietary modulators of brain functions
1108. Plant polyphenols as natural drugs for the management of Down syndrome and related disorders
1109. Plants as potential sources for drug development against Alzheimer’s disease
1110. Plants traditionally used in age-related brain disorders (dementia): an ethanopharmacological survey
1111. Plants with traditional uses and activities, relevant to the management of Alzheimer’s disease and other cognitive disorders
1112. Plasma antioxidant status in patients with Alzheimer’s disease and cognitively intact elderly: a meta-analysis of case-control studies
1113. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson’s disease
1114. Plasticity of hippocampal synaptic transmission and intrinsic excitability in a mouse model of Alzheimer’s disease
1115. Polymethoxyflavones: Novel β-secretase (BACE1) inhibitors from citrus peels
1116. polyphenol amentoflavone affords neuroprotection against neonatal hypoxic‐ischemic brain damage via multiple mechanisms
1117. polyphenol antioxidants from natural sources and contribution to health promotion
1118. polyphenol composition, antioxidant and bioplaguicide activities of the solid residue from hydrodistillation of Rosmarinus officinalis L.
1119. polyphenol compounds and PKC signaling
1120. polyphenol health effects on cardiovascular and Neurodegenerative disorders: A review and meta-analysis
1121. polyphenol modulation of blood flow and oxygenation
1122. polyphenol Pharmacokinetics and Cardiovascular, Cognitive and Exercise Pharmacodynamics following Montmorency Tart Cherry Intake in Humans
1123. polyphenol stilbenes: molecular mechanisms of defence against oxidative stress and aging-related diseases
1124. Polyphenol-enriched cocoa protects the diabetic retina from glial reaction through the sirtuin pathway
1125. Polyphenol-rich Boswellia serrata gum prevents cognitive impairment and insulin resistance of diabetic rats through inhibition of GSK3β activity, oxidative …
1126. Polyphenol-rich foods in the Mediterranean diet are associated with better cognitive function in elderly subjects at high cardiovascular risk
1127. Polyphenolic antioxidants and neuronal regeneration
1128. Polyphenolic Compound from Vitis vinifera L. have Potential for the Alzheimer Disease Treatment
1129. Polyphenolic compounds for treating Neurodegenerative disorders involving protein misfolding
1130. Polyphenols and brain health
1131. Polyphenols and cognitive function
1132. Polyphenols and health: new and recent advances
1133. Polyphenols and human health: a review
1134. Polyphenols and human health: prevention of disease and mechanisms of action
1135. Polyphenols and inflammation
1136. Polyphenols and Metabolites Enhance Survival in Rodents and Nematodes—Impact of Mitochondria
1137. Polyphenols and Neurodegenerative diseases
1138. Polyphenols and Neurodegenerative Diseases
1139. Polyphenols and neuroprotection against ischemia and neurodegeneration
1140. Polyphenols and public health
1141. Polyphenols and the human brain: plant “secondary metabolite” ecologic roles and endogenous signaling functions drive benefits
1142. Polyphenols as acetylcholinesterase inhibitors: structural specificity and impact on human disease
1143. Polyphenols As Natural, Dual-Action Therapeutics For Alzheimer’s Disease
1144. Polyphenols beyond barriers: a glimpse into the brain
1145. Polyphenols derived from lychee seed suppress Aβ (1-42)-induced neuroinflammation
1146. Polyphenols for diabetes associated neuropathy: Pharmacological targets and clinical perspective
1147. Polyphenols from Food and Natural Products: Neuroprotection and Safety
1148. Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative
1149. Polyphenols in dementia: From molecular basis to clinical trials
1150. Polyphenols in disease: from diet to supplements
1151. Polyphenols in health and disease: practice and mechanisms of benefits
1152. Polyphenols in neurodegeneration and neuroendocrine alterations: a metabolomic approach
1153. Polyphenols in Parkinson’s disease: A systematic review of in vivo studies
1154. Polyphenols in the Prevention of Alzheimer’s Disease: some food for thought?
1155. Polyphenols Modulate Alzheimer’s Amyloid Beta Aggregation in a Structure-Dependent Manner
1156. Polyphenols neuroprotective effect in a Parkinson’s disease yeast model: phosphoproteome alterations
1157. Polyphenols suppress and modulate inflammation: possible roles in health and disease
1158. Polyphenols Targeting Brain Cells Longevity, Brain’s Redox Status, and Neurodegenerative Diseases
1159. Polyphenols-What’s Behind their Antiaging Brain Reputation
1160. Polyphenols: a diverse class of multi-target anti-HIV-1 agents
1161. Polyphenols: Food sources and health benefits
1162. Polyphenols: multipotent therapeutic agents in Neurodegenerative diseases
1163. Polyphenols: well beyond the antioxidant capacity: gallic acid and related compounds as neuroprotective agents: you are what you eat!
1164. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer’s disease
1165. Pomegranate’s neuroprotective effects against Alzheimer’s disease are mediated by urolithins, its ellagitannin-gut microbial derived metabolites
1166. Possible involvement of programmed cell death pathways in the neuroprotective action of polyphenols
1167. Possible role of common spices as a preventive and therapeutic agent for Alzheimer’s disease
1168. Possible therapeutic role of grape (Vitis vinifera) leaves polyphenolic extract in the regression of aluminium-induced Alzheimer’s disease in rats
1169. Possible Therapeutic Uses of Salvia triloba and Piper nigrum in Alzheimer’s Disease–Induced Rats
1170. Potent anti‐amyloidogenic and fibril‐destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer’s disease
1171. Potent Inhibitory Effect of flavonoids in Scutellaria baicalensis on Amyloid β Protein-Induced Neurotoxicity
1172. Potential application of dietary polyphenols from red wine to attaining healthy ageing
1173. Potential beneficial effects of a diet with walnuts in aging and Alzheimer’s disease
1174. Potential complementarity of high-flavanol cocoa powder and spirulina for health protection
1175. Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro
1176. Potential health benefits of tea polyphenols—a review
1177. Potential of medicinal plant compounds to targeting Tau protein in the therapy of Alzheimer’s disease–A review
1178. Potential of South African medicinal plants targeting the reduction of Aβ42 protein as a treatment of Alzheimer’s disease
1179. Potential protection of green tea polyphenols against 1800 MHz electromagnetic radiation-induced injury on rat cortical neurons
1180. Potential role of (-)-epigallocatechin-3-gallate (EGCG) in the secondary prevention of Alzheimer disease
1181. Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease
1182. Potential role of olive oil phenolic compounds in the prevention of Neurodegenerative diseases
1183. Potential Role of Vitamin C in the Prevention of Alzheimer’s Disease
1184. Potential therapeutic strategies for Alzheimer’s disease targeting or beyond β-amyloid: insights from clinical trials
1185. Potential therapeutic strategies to prevent the progression of alzheimer to disease states
1186. Precautionary Ellagic Acid Treatment Ameliorates Chronically Administered Scopolamine Induced Alzheimer’s Type Memory and Cognitive Dysfunctions in …
1187. Preclinical and potential applications of common western herbal supplements as complementary treatment in Parkinson’s disease
1188. Precursor form of brain‐derived neurotrophic factor and mature brain‐derived neurotrophic factor are decreased in the pre‐clinical stages of Alzheimer’s disease
1189. Prediction of Anti‐Alzheimer’s Activity of flavonoids Targeting Acetylcholinesterase in silico
1190. Prenylated flavonoids from the Roots of Sophora flavescens Promote Vascular Relaxation via Endothelium-Dependent Mechansims
1191. Pretreatment with natural flavones and neuronal cell survival after oxidative stress: a structure− activity relationship study
1192. Prevention and reversal of Alzheimer’s disease: treatment protocol
1193. Prevention and treatment of Alzheimer disease and aging: antioxidants
1194. Prevention of Dementia
1195. Prevention of oxidative injury by flavonoids from stems and leaves of Scutellaria Baicalensis georgi in PC12 cells
1196. Preventive and Therapeutic Effects of Traditional Medicines on Diabetic Complications: Sophora flavescens, Pueraria lobata, Coptis chinensis, Cirsium …
1197. Preventive effect of small-leaved kuding tea (Ligustrum robustum (Roxb.) Bl.) polyphenols on D-galactose-induced oxidative stress and aging in mice
1198. PREVENTIVE EFFECTS OF GREEN TEA CATECHINS ON DEMENTIA
1199. Primary Prevention of Alzheimer’s Disease (AD)
1200. Processing of the β‐amyloid precursor protein and its regulation in Alzheimer’s disease
1201. Profiling of in vitro neurobiological effects and phenolic acids of selected endemic Salvia species
1202. Progress in drug development for Alzheimer’s disease: an overview in relation to mitochondrial energy metabolism
1203. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset.
1204. Proposed Mechanism of Alzheimer’s Disease: the Role of oxidative stress A Review of Scientific Literature
1205. Prospective associations between single foods, Alzheimer’s dementia and memory decline in the elderly
1206. Protection of Okadaic Acid-induced Tau Hyperphosphorylation by Bioflavonoids in Neuroblastoma Cells
1207. Protective effect of a (poly) phenol-rich extract derived from sweet cherries culls against oxidative cell damage
1208. Protective effect of a phenolic‐rich fraction from Schisandra chinensis against H2O2‐induced apoptosis in SH‐SY5Y cells
1209. Protective effect of black tea extract against aluminium chloride-induced Alzheimer’s disease in rats: A behavioural, biochemical and molecular approach
1210. Protective effect of daidzein against streptozotocin‐induced Alzheimer’s disease via improving cognitive dysfunction and oxidative stress in rat model
1211. Protective effect of ginger (Zingiber officinale) on Alzheimer’s disease induced in rats
1212. Protective Effect of Green Tea Extract on Neuronal Cell Death in Alzheimer Model using -amyloid Peptide
1213. Protective effect of green tea polyphenol EGCG against neuronal damage and brain edema after unilateral cerebral ischemia in gerbils
1214. Protective effect of iris germanica l. In β-amyloid-induced animal model of Alzheimer’s disease
1215. Protective effect of isoflavones from Trifolium pratense on dopaminergic neurons
1216. Protective effect of kaempferol on the transgenic Drosophila model of Alzheimer’s disease
1217. Protective effect of mulberry crude extract against nonylphenol-induced thyroid disruption by inhibiting the activity of deiodinase in rats
1218. Protective effect of naringin, a citrus flavonoid, against colchicine-induced cognitive dysfunction and oxidative damage in rats
1219. Protective effect of Picrorhiza kurroa on Alzheimer’s disease induced by aluminium chloride in rats
1220. Protective effect of raisin (currant) against spatial memory impairment and oxidative stress in Alzheimer disease model
1221. Protective effect of rutin, a polyphenolic flavonoid against haloperidol‐induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical …
1222. Protective effect of standardized extract of Passiflora incarnata flower in Parkinson’s and Alzheimer’s disease
1223. Protective Effect of the Leaves of Solanum torvums wartz on Drosophila melanogaster against β-Amyloid Induced Alzheimer Disease
1224. Protective effects of berry polyphenols against age-related cognitive impairment
1225. Protective effects of dietary polyphenols in human diseases and mechanisms of action
1226. Protective effects of fisetin and other berry flavonoids in Parkinson’s disease
1227. Protective effects of flavonoid baicalein against menadione-induced damage in SK-N-MC cells
1228. Protective effects of flavonoids against Alzheimer’s disease-related neural dysfunctions
1229. Protective effects of foods containing flavonoids on age-related cognitive decline
1230. Protective effects of gingerol on streptozotocin-induced sporadic Alzheimer’s disease: emphasis on inhibition of β-amyloid, COX-2, alpha-, beta-secretases …
1231. Protective effects of Indian spice curcumin against amyloid-β in Alzheimer’s disease
1232. Protective effects of Portulaca oleracea against rotenone mediated depletion of glutathione in the striatum of rats as an animal model of Parkinson’s disease
1233. Protective effects of water extract of propolis on dopaminergic neurons, brain derived neurotrophic factor and stress oxidative factors in the rat model of Parkinson’s …
1234. Protective role of caffeic acid in an Aβ25-35-induced Alzheimer’s disease model
1235. Protein drug targets of lavandula angustifolia on treatment of rat Alzheimer’s disease
1236. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds
1237. Proteomics in traditional Chinese medicine with an emphasis on Alzheimer’s disease
1238. Putative role of red wine polyphenols against brain pathology in Alzheimer’s and Parkinson’s disease
1239. Quercetin enrich diet during the early-middle not middle-late stage of Alzheimer’s disease ameliorates cognitive dysfunction
1240. Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer’s disease
1241. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution
1242. Rational approach to discover multipotent anti-Alzheimer drugs
1243. Rational Design, Preparation, and Analysis of Chemical Reagents for Investigating Multiple Pathological Factors in Alzheimer’s Disease
1244. Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson’s disease
1245. Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region
1246. Recent advances from metabolomics and lipidomics application in Alzheimer’s disease inspiring drug discovery
1247. Recent advances in health promoting effect of dietary polyphenols
1248. Recent advances in herbal medicines treating Parkinson’s disease
1249. Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present)
1250. Recent Advances in Nanoencapsulation Systems Using PLGA of Bioactive Phenolics for Protection against Chronic Diseases
1251. Recent advances in the antioxidant therapies for Alzheimer’s disease: Emphasis on natural antioxidants
1252. Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer’s disease therapy
1253. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer’s?
1254. Recent advances in the genetics of Parkinson’s disease
1255. Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer’s disease
1256. Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer’s Disease
1257. Recent findings in Alzheimer disease and nutrition focusing on epigenetics
1258. Recent Plant Based Remedies for Alzheimer’s Disease, Parkinson’s Disease and Cerebral Ischemic Stroke
1259. Recent progress in multifunctional metal chelators as potential drugs for Alzheimer’s disease
1260. Recent Studies on Mechanisms of New Drug Candidates for Alzheimer’s Disease Interacting with Amyloid-β Protofibrils Using Molecular Dynamics Simulations
1261. Recent trends in drug discovery against Alzheimer’s disease: use of natural products and nutraceuticals from botanicals
1262. Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental models of Parkinson’s disease
1263. Recent updates on the association between Alzheimer’s disease and vascular dementia
1264. Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
1265. Receptor specific, stimuli responsive and subcellular targeted approaches for effective therapy of Alzheimer: Role of surface engineered nanocarriers
1266. Recovery of new diarylheptanoid sources in Betulaceae: Characterisation of the phenolic profile of Corylus species by HPLC-ESI-MS methods
1267. Recycling acetate for improving flavanones production from Escherichia coli
1268. Red grape juice and Alzheimer’s disease
1269. Red wine polyphenol-induced, endothelium-dependent NO-mediated relaxation is due to the redox-sensitive PI3-kinase/Akt-dependent phosphorylation of …
1270. Red wine retards Abeta deposition and neuroinflammation in Alzheimer’s disease
1271. Red wine, resveratrol, and Alzheimer’s disease
1272. Redox chemistry of green tea polyphenols: therapeutic benefits in Neurodegenerative diseases
1273. Reduction is the New Youth: The Effect of Polyphenols on Brain Aging and Diseases
1274. Regulation of autophagy by polyphenols: Paving the road for treatment of neurodegeneration
1275. Relationship between Wine Consumption and Alzheimer’s Disease
1276. Relationship of Wine Consumption with Alzheimer’s Disease
1277. Relationships of dietary patterns, foods, and micro-and macronutrients with Alzheimer’s disease and late-life cognitive disorders: a systematic review
1278. Research Article Improvement of Learning and Memory by Morin, A flavonoid in Young and Aged Mice
1279. Research of polyphenols with neuroprotective potential in a yeast model of degeneration
1280. Restoration of stressor-induced calcium dysregulation and autophagy inhibition by polyphenol-rich açaí (Euterpe spp.) fruit pulp extracts in rodent brain cells in vitro
1281. Resveratrol and Grape’s Extract-Loaded Solid Lipid Nanoparticles for the Treatment of Parkinson’s and Alzheimer’s Diseases
1282. Resveratrol as a potential therapeutic candidate for the treatment and management of Alzheimer’s disease
1283. Resveratrol—a boon for treating Alzheimer’s disease?
1284. Retrospect and prospect of active principles from Chinese herbs in the treatment of dementia
1285. Reverse Alzheimer’s Disease Naturally: Alternative Treatments for dementia including Alzheimer’s Disease
1286. Review of natural products on Parkinson’s disease pathology
1287. Review of Traditional and Natural Methods of Treating Alzheimer’s Disease
1288. REVIEW ON CURRENT TREATMENT STRATEGY IN Alzheimer’s DISEASE AND ROLE OF HERBS IN TREATING NEUROLOGICAL DISORDERS
1289. Review on potential phytocompounds in drug development for Parkinson disease: a pharmacoinformatic approach
1290. Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective
1291. Rhodiola rosea L. and Alzheimer’s Disease: From Farm to Pharmacy
1292. Rhodiola rosea L.-An evaluation of safety and efficacy in the context of a neurological disorder, Alzheimer Disease
1293. Role of Acetylcholinesterase Inhibitors and Alzheimer Disease
1294. Role of alpha-synuclein primary structure and oxidative stressin Parkinson’s disease pathology
1295. Role of amyloid-β–metal interactions in Alzheimer’s disease
1296. Role of flavonoids in Neurodegenerative Disorders with Special Emphasis on Tangeritin
1297. Role of flavonoids in oxidative stress
1298. ROLE OF HESPERETIN & PYRIDOXINE PROTECT IN THE NIGROSTRIATAL DOPAMINERGIC PROJECTION IN A NEUROTOXIN MODEL OF PARKINSON’S
1299. Role of intestinal microbiota in the generation of polyphenol‐derived phenolic acid mediated attenuation of Alzheimer’s disease β‐amyloid oligomerization
1300. Role of medicinal plants against Alzheimer’s disease
1301. Role of medicinal plants in Neurodegenerative diseases with special emphasis to alzheimer’s
1302. Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer’s disease
1303. Role of Nutraceuticals in Alzheimer’s disease
1304. Role of p38/MAPKs in Alzheimer’s disease: implications for amyloid beta toxicity targeted therapy
1305. Role of plant polyphenols in Alzheimer’s disease
1306. Role of plant-derived flavonoids and their mechanism in attenuation of Alzheimer’s and Parkinson’s diseases: An update of recent data
1307. Role of polyphenols in cell death control
1308. Role of Polyphenols in the prevention of neurodegeneration
1309. Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer’s and Parkinson’s diseases
1310. Role of standardized grape polyphenol preparation as a novel treatment to improve synaptic plasticity through attenuation of features of metabolic syndrome in a …
1311. Role of the APP non-amyloidogenic signaling pathway and targeting α-secretase as an alternative drug target for treatment of Alzheimer’s disease
1312. Role of the Microbiome in polyphenol Metabolite-Mediated Attenuation of β-amyloid and tau Protein Misfolding in Alzheimer’s Disease
1313. Roles of AMP-activated protein kinase in Alzheimer’s disease
1314. Rosmarinic acid suppresses Alzheimer’s disease development by reducing amyloid β aggregation by increasing monoamine secretion
1315. Roundoc Rx: Neurodegenerative Disease: Part 2—Top Herbs and Supplements for Addressing Alzheimer’s and Parkinson’s Disease
1316. Rutin as a natural therapy for Alzheimer’s disease: Insights into its mechanisms of action
1317. Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson’s disease
1318. Screening and evaluation of natural compounds for therapeutic application in Alzheimer’s disease
1319. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer’s disease and in other Neurodegenerative diseases
1320. Secretase inhibitors for the treatment of Alzheimer’s disease: Long road ahead
1321. Secretory phospholipase A2-IIA in Alzheimer’s disease and inflammatory responses in astrocytes
1322. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains
1323. Separations with Raman Spectroscopy for Identification of Oxidatively Modified Components in Parkinson’s Disease
1324. Serum concentrations of vitamin E and carotenoids are altered in Alzheimer’s disease: A case-control study
1325. Several targets involved in Alzheimer’s disease amyloidogenesis are affected by morin and isoquercitrin
1326. Shaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases
1327. Short-term dietary supplementation of blueberry polyphenolics: beneficial effects on aging brain performance and peripheral tissue function
1328. Short-term dietary supplementation of blueberry polyphenolics: beneficial effects on aging brain performance and peripheral tissue function
1329. Signal transduction in Alzheimer disease: p21‐activated kinase signaling requires C‐terminal cleavage of APP at Asp664
1330. Signaling pathway cross talk in Alzheimer’s disease
1331. Significant roles of neuroinflammation in Parkinson’s disease: therapeutic targets for PD prevention
1332. Silymarin attenuated the amyloid β plaque burden and improved behavioral abnormalities in an Alzheimer’s disease mouse model
1333. Silymarin’s inhibition and treatment effects for Alzheimer’s disease
1334. Simple In Vivo Models of Alzheimer’s Disease
1335. Simultaneous determination of phenolic compounds in Catharanthus roseus leaves by HPLC method
1336. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases
1337. Sir-2.1 mediated attenuation of α-synuclein expression by Alaskan bog blueberry polyphenols in a transgenic model of Caenorhabditis elegans
1338. Sirtuins as novel targets for Alzheimer’s disease and other Neurodegenerative disorders: experimental and genetic evidence
1339. Sirtuins in Alzheimer’s disease: SIRT2-related genophenotypes and implications for pharmacoepigenetics
1340. Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues
1341. Small molecule natural products and Alzheimer’s disease
1342. Sophora Tomentosa Extract Prevents MPTP-Induced Parkinsonism in C57BL/6 Mice Via the Inhibition of GSK-3β Phosphorylation and Oxidative Stress
1343. Spices And Herbs: An Essential Guide To Spice Up Your Health And Flavor Your Diet
1344. ß-Amyloid and oxidative stress in the Pathogenesis of Alzheimer’s Disease
1345. Stahl’s Illustrated Alzheimer’s Disease and Other Dementias
1346. Statistical and Data Mining Methodologies for Behavioral Analysis in Transgenic Mouse Models of Alzheimer’s Disease: Parallels with Human AD Evaluation
1347. Stem Cell Biology for Therapeutic Development in Parkinson’s Disease
1348. STEM CELL-BASED THERAPY FOR Alzheimer’s DISEASE
1349. Stem Cells as Potential Targets of Polyphenols in Multiple Sclerosis and Alzheimer’s Disease
1350. Strategies for Multi-target Directed Ligands: Application in Alzheimer’s Disease (AD) Therapeutics
1351. Structural Analysis of Flavonoid/Drug Target Complexes: Natural Products as Lead Compounds for Drug Development
1352. Structural Elucidation of Novel Phenolic Glycosides in Cimicifugae Rhizoma by Structure-based Chemical Screening using LC-NMR and LC-UV-MS
1353. Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity
1354. Structure-activity relationships of flavonoids
1355. Structure–activity relationships of acetylated flavone glycosides from Galeopsis ladanum L.(Lamiaceae)
1356. Studies on Amyloid Beta Peptide Aggregation and Its Modulation by Garlic Components: Relevance to Alzheimer’s Disease
1357. Studies on the Leaves of Punica Granatum Linn. and its Invitro Inhibition of Ache for Potential Use in Alzheimer’s Treatment
1358. Study of oxidative stress and Alzheimer’s disease in transgenic mice and pharmacological agents to counteract nutritional deficiency
1359. Study of Possible neuroprotective Effects of Certain Drugs on Experimentally Induced Parkinson’s Disease in Rats
1360. Study on neuroprotective capacity of key flavonoids of ampelopsis grossedentata
1361. Sub-critical solvent extraction of flavonoid-rich grape by-products
1362. Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer’s Disease: A Systematic Review
1363. Supplementation with vitamins E plus C or soy isoflavones in ovariectomized rats: effect on the activities of Na+, K+-ATPase and cholinesterases
1364. Suppression of presymptomatic oxidative stress and inflammation in neurodegeneration by grape-derived polyphenols
1365. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity
1366. Sweet Cherry Phenolic Compounds: Identification, Characterization, and Health Benefits
1367. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease
1368. Synergistic action of melatonin in combination with Anti-Parkinsonian drugs in experimental model of parkinson s disease
1369. Synergistic antioxidant action of vitamin E and rutin SNEDDS in ameliorating oxidative stress in a Parkinson’s disease model
1370. Synergistic Effect of Selected Hydroxy Cinnamic Acid Derivative (HCA) With Rivastigmine in Dementia
1371. Synergistic neuroprotective effects of Withania somnifera with specific dietary derived polyphenols
1372. Synergistic properties of bioavailable phenolic compounds from olive oil: electron transfer and neuroprotective properties
1373. Synthesis and antioxidant activity of phenolic amides
1374. Synthesis and biological evaluation of novel homoisoflavonoids for retinal neovascularization
1375. Synthesis and Development of BACE 1 Inhibitor for Alzheimer’s Diseases from Medicinal Plants
1376. Synthesis and evaluation of neuroprotective selenoflavanones
1377. Synthesis of Isooctyl Phenol Analogs from Insect-Flower
1378. Synthesis of phenolic amides and evaluation of their antioxidant and anti-inflammatory activity in vitro and in vivo
1379. Systems pharmacology based approach to investigate the in-vivo therapeutic efficacy of Albizia lebbeck (L.) in experimental model of Parkinson’s disease
1380. T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer’s disease: potential pools of new biomarkers
1381. Target-based selection of flavonoids for Neurodegenerative disorders
1382. Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
1383. Targeting dysregulation of brain iron homeostasis in Parkinson’s disease by iron chelators
1384. Targeting ERK signaling pathway by polyphenols as novel therapeutic strategy for neurodegeneration
1385. Targeting Inflammatory Pathways in Alzheimer’s Disease: A Focus on Natural Products and Phytomedicines
1386. Targeting miRNAs by polyphenols: novel therapeutic strategy for aging
1387. Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators
1388. Targeting NADPH Oxidase and Phospholipases A2 in Alzheimer’s Disease
1389. Targeting Parkinson’s-tyrosine hydroxylase and oxidative stress as points of interventions
1390. Targeting the Nrf2/amyloid-beta liaison in Alzheimer’s disease: A rational approach
1391. Targeting the progression of Parkinson’s disease
1392. Targeting α-synuclein aggregation for Parkinson’s disease treatment
1393. Targeting α-Synuclein as a Parkinson’s Disease Therapeutic
1394. Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches
1395. Tea and Parkinson’s disease: Constituents of tea synergize with antiparkinsonian drugs to provide better therapeutic benefits
1396. Tea flavonoids and their effect on chronic inflammation induced in Trypanosoma brucei brucei infected mice
1397. Tea-Derived Polyphenols and Stilbenes on Amyloid Neurotoxicity
1398. The ability of three African herbal remedies to offer protection against an in vitro model of Parkinson’s disease
1399. The action of polyphenols in diabetes mellitus and Alzheimer’s disease: A common agent for overlapping pathologies
1400. The Alzheimer’s Prevention Cookbook: 100 Recipes to Boost Brain Health
1401. The amyloid beta peptide: a chemist’s perspective. Role in Alzheimer’s and fibrillization
1402. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal
1403. The anti-amyloidogenic effect is exerted against Alzheimer’s β-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure
1404. The Antimicrobial Activity Mechanism of Sophoraflavanone B against Methicillin-Resistant Staphylococcus aureus
1405. The antioxidant properties of 4–quinolones compared to structurally related flavonoids
1406. The Association Between Dietary flavonoid Intake and Chronic Obstructive Pulmonary Disease, Systemic Inflammation, and Comorbidity Burden
1407. The beneficial and deleterious role of dietary polyphenols on chronic degenerative diseases by regulating gene expression
1408. The beneficial effects of dietary flavonoids: Sources, bioavailability and biological functions
1409. The beneficial effects of fruit polyphenols on brain aging
1410. The beneficial role of Naringin-a citrus bioflavonoid, against oxidative stress-induced neurobehavioral disorders and cognitive dysfunction in rodents: A systematic …
1411. THE BENEFITS OF RESVERATROL WITH POLYPHENOLS IN Parkinson’s DISEASE WITH Alzheimer’s CHANGES
1412. The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson’s disease
1413. The cascade of oxidative stress and tau protein autophagic dysfunction in Alzheimer’s disease
1414. The Change of Neurotransmitters in Plasma of dementia Patients after Aromatherapy.
1415. The Crocus sativus compounds trans-crocin 4 and trans-crocetin modulate the amyloidogenic pathway and tau misprocessing in Alzheimer disease neuronal cell …
1416. The development of preventives and therapeutics for Alzheimer’s disease that inhibit the formation of β-amyloid fibrils (fAβ), as well as destabilize preformed fAβ
1417. The Effect of Essential Oil on Plasma Level of 5-HT in dementia Patients
1418. The effect of Ginkgo biloba extract on parkinsonisminduced biochemical changes in brain of irradiated rats
1419. The effect of green tea consumption on oxidative stress markers and cognitive function in patients with Alzheimer’s disease: A prospective intervention study
1420. The effect of polyphenols on protein degradation pathways: implications for neuroprotection
1421. The effect of Scutellaria baicalensis stem-leaf flavonoids on spatial learning and memory in chronic cerebral ischemia-induced vascular dementia of rats
1422. The effects of flavonoid and other polyphenol consumption on cognitive performance: a systematic research review of human experimental and epidemiological …
1423. The effects of the flavonoid baicalein and osmolytes on the Mg 2+ accelerated aggregation/fibrillation of carboxymethylated bovine 1SS-α-lactalbumin
1424. The Effects of the Green Tea polyphenol Epigallocatechin Gallate on the Central Nervous, Endocrine, and Innate Immune Systems
1425. The epidemiology of Parkinson’s disease: risk factors and prevention
1426. The flavanol (−)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against …
1427. The flavone luteolin improves central nervous system disorders by different mechanisms: a review
1428. The flavonoid baicalein promotes NMDA receptor‐dependent long‐term potentiation and enhances memory
1429. The flavonoid Derivative 2-(4′ Benzyloxyphenyl)-3-hydroxy-chromen-4-one Protects Against Aβ42-Induced Neurodegeneration in Transgenic Drosophila: Insights …
1430. The flavonoid quercetin ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model …
1431. The flavonoids ameliorates: protective mechanisms in Neurodegenerative diseases
1432. The GC-MS analyses of the n-hexane extract of Nitraria schoberi L., its total phenolics and in vitro antioxidant activity
1433. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide‐induced toxicity: involvement of its flavonoid constituents and protein …
1434. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide‐induced toxicity: involvement of its flavonoid constituents and protein …
1435. The Ginkgo biloba extract EGb 761® and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex
1436. The gut microbiota links dietary polyphenols with management of psychiatric mood disorders
1437. The Healthy Mind Cookbook: Big-flavor Recipes to Enhance Brain Function, Mood, Memory, and Mental Clarity
1438. The immunomodulatory and anti-inflammatory role of polyphenols
1439. The impact of flavonoids on memory: physiological and molecular considerations
1440. The impact of fruit flavonoids on memory and cognition
1441. The impact of gastrointestinal modifications, blood-brain barrier transport, and intracellular metabolism on polyphenol bioavailability: an overview
1442. The influence of beverage composition on delivery of phenolic compounds from coffee and tea
1443. The influence of common free radicals and antioxidants on development of Alzheimer’s Disease
1444. The influence of oxidative stress in Alzheimer’s disease-possible beneficial relevance of the antioxidants from wheatgrass juice. Review Article
1445. The influence of plant extracts on Ȼ Amyloid induced pathologies in an APP/PS1 mouse model of Alzheimer’s disease
1446. The interactions of flavonoids within neuronal signalling pathways
1447. The mechanisms of action of flavonoids in the brain: direct versus indirect effects
1448. The medicinal chemistry of natural and semisynthetic compounds against Parkinson’s and Huntington’s diseases
1449. The Mind Diet: A Scientific Approach to Enhancing Brain Function and Helping Prevent Alzheimer’s and Dementia
1450. The molecular basis of the prevention of Alzheimer’s disease through healthy nutrition
1451. The molecular basis of working mechanism of natural polyphenolic antioxidants
1452. The n-Butanol Fraction and Rutin from Tartary Buckwheat Improve Cognition and Memory in an In Vivo Model of Amyloid-β-Induced Alzheimer’s Disease
1453. The neuroprotective effect and action mechanism of polyphenols in diabetes mellitus-related cognitive dysfunction
1454. The neuroprotective effects of cocoa flavanol and its influence on cognitive performance
1455. The neuroprotective potential of flavonoids: a multiplicity of effects
1456. The neuroprotective potential of phenolic-enriched fractions from four Juniperus species found in Portugal
1457. The Nrf2/HO-1 Axis as Targets for Flavanones: Neuroprotection by Pinocembrin, Naringenin, and Eriodictyol
1458. The Nutritional Components of Beer and Its Relationship with Neurodegeneration and Alzheimer’s Disease
1459. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer’s disease
1460. The oxidative stress hypothesis in Alzheimer’s disease
1461. The potential of flavonoids for the treatment of Neurodegenerative diseases
1462. The potential role of dietary polyphenols in Parkinson’s disease
1463. The prenylflavonoid xanthohumol reduces Alzheimer-like changes and modulates multiple pathogenic molecular pathways in the neuro2a/APPswe cell …
1464. The present and future of pharmacotherapy of Alzheimer’s disease: A comprehensive review
1465. The protective role of plant biophenols in mechanisms of Alzheimer’s disease
1466. The relevance body mass index on the oxidative stress status of Alzheimer’s disease pathology
1467. The role of dietary coconut for the prevention and treatment of Alzheimer’s disease: potential mechanisms of action
1468. The Role of HIV-1 Proteins in Alzheimer’s Disease Pathology
1469. The role of iron-induced fibrin in the pathogenesis of Alzheimer’s disease and the protective role of magnesium
1470. The role of lifestyle factors in cognitive aging and dementia
1471. The role of lipids and membranes in the pathogenesis of Alzheimer’s disease: a comprehensive view
1472. The role of natural products in Alzheimer’s and Parkinson’s disease
1473. The role of natural products in the discovery of new drug candidates for the treatment of Neurodegenerative disorders II: Alzheimer’s disease
1474. The role of nutrient-based epigenetic changes in buffering against stress, aging, and Alzheimer’s disease
1475. The role of nutrition in the prevention and treatment of dementia
1476. The Role of oxidative stress and Cholesterol in Animal Models of Alzheimer’s Disease
1477. The role of phenolic OH groups of flavonoid compounds with H-bond formation ability to suppress amyloid mature fibrils by destabilizing β-sheet conformation …
1478. The role of phytochemicals in the treatment and prevention of dementia
1479. The role of polyphenolic antioxidants in health, disease, and aging
1480. The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer’s disease
1481. The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: a mini review
1482. The role of rutin and diosmin, two citrus polyhydroxyflavones in disease prevention and treatment
1483. The role of the ubiquitin proteasome system in Alzheimer’s disease
1484. The Safe and Effective Applications of Essential Oils in Alzheimer’s Dementia
1485. The science of cocoa flavanols: bioavailability, emerging evidence, and proposed mechanisms
1486. The Simplicity of dementia A Guide for Family and Carers
1487. The Structural Hybrids of Acetylcholines-terase Inhibitors in the Treatment of Alzheimer’s Disease: A Review
1488. The therapeutic potential of rosemary (Rosmarinus officinalis) diterpenes for Alzheimer’s disease
1489. The Therapeutic Role of Turmeric in Treatment and Prevention of Alzheimer’s Disease
1490. The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies
1491. The Treatment of Brain Inflammation in Alzheimer’s Disease. Can Traditional Medicines Help?
1492. The use of cell-free systems to characterize Parkinson’s disease-related gene products
1493. The use of flavonoids in central nervous system disorders
1494. The use of herbal medicine in Alzheimer’s disease—a systematic review
1495. The Use of herbal supplements on minimizing the clinical manifestations of Alzheimer’s disease
1496. The Use of Polyphenols for the Treatment of Alzheimer’s Disease
1497. Therapeutic Advancement in Alzheimer Disease: New Hopes on the Horizon?
1498. Therapeutic agents in Alzheimer’s disease through a multi-targetdirected ligands strategy: recent progress based on tacrine core
1499. Therapeutic approaches to Alzheimer’s disease through stimulating of non-amyloidogenic processing of amyloid precursor protein
1500. Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson’s disease
1501. Therapeutic effect of modulating TREM-1 via anti-inflammation and autophagy in Parkinson’s disease
1502. Therapeutic effects of Cyperus rotundus rhizome extract on memory impairment, neurogenesis and mitochondria in beta-amyloid rat model of Alzheimer’s disease
1503. Therapeutic impact of grape leaves polyphenols on certain biochemical and neurological markers in AlCl3-induced Alzheimer’s disease
1504. Therapeutic implications of anti-inflammatory natural products in Alzheimer’s disease
1505. Therapeutic interventions for the suppression of Alzheimer’s disease: quest for a remedy
1506. Therapeutic potential of baicalein in Alzheimer’s disease and Parkinson’s disease
1507. Therapeutic Potential Of Catechins And Derivatives For The Prevention Of Alzheimer’s
1508. Therapeutic Potential Of Catechins And Derivatives For The Prevention Of Alzheimer’s Disease
1509. Therapeutic potential of luteolin in transgenic Drosophila model of Alzheimer’s disease
1510. Therapeutic potential of natural products in Parkinson’s disease
1511. Therapeutic Potential of Polyphenols from Epilobium Angustifolium (Fireweed)
1512. Therapeutic Potential of Polyphenols in Parkinson’s Disease
1513. Therapeutic potentials of herbal drugs for Alzheimer’s disease—An overview
1514. Therapeutic potentials of microalgae in the treatment of Alzheimer’s disease
1515. Therapeutic potentials of plant iridoids in Alzheimer’s and Parkinson’s diseases: A review
1516. Therapeutic role of sirtuins in Neurodegenerative disease and their modulation by polyphenols
1517. Therapeutic strategies targeting amyloid-β in Alzheimer’s disease
1518. Therapeutics of Alzheimer’s disease: Past, present and future
1519. Therapies for Parkinson’s diseases: alternatives to current pharmacological interventions
1520. Therapies for prevention and treatment of Alzheimer’s disease
1521. Thymus pulegioides L. as a rich source of antioxidant, anti-proliferative and neuroprotective phenolic compounds
1522. Tissue injury by reactive oxygen species and the protective effects of flavonoids
1523. To Study The Ameliorative Effect Of Hydroalcholic Extract Of Caryota urens (Arecaceae) On Streptozotocin Induced Alzheimer’s Model In Mice
1524. Tomato (Lycopersicon esculentum) seeds: new flavonols and cytotoxic effect
1525. Tools of the trade: investigations into design strategies of small molecules to target components in Alzheimer’s disease
1526. Total and specific polyphenol intakes in midlife are associated with cognitive function measured 13 years later
1527. Total Phenolic and flavonoid Content and Biological Activities of Extracts and Isolated Compounds of Cytisus villosus Pourr.
1528. Total Phenolic, Flavonoid, Fatty Acid Contents and Cytotoxic, Antioxidant, and Antimicrobial Activities of Hedysarum aucheri
1529. Total Synthesis of an C-CH2-C Linked Ochnaflavone
1530. Total Synthesis of Ochnaflavone Analogs Having CNH-C and CSC Linkages
1531. Total Synthesis of Ochnaflavone, A Potent Plant-originated Biflavonoid with Anti-inflammatory Activity
1532. Towards a bioinformatics analysis of anti-Alzheimer’s herbal medicines from a target network perspective
1533. Toxic exposure and life style factors on ageing brain Neurodegenerative disease, Alzheimer’s and Parkinson’s: Role of natural antioxidants to ameliorate the condition
1534. Traditional and modern medicine harmonizing the two approaches in the treatment of neurodegeneration (Alzheimer’s disease-AD)
1535. Traditional Chinese medicines and Alzheimer’s disease
1536. Traditional Medicine in the Treatment of dementia and Alzheimer’s Disease
1537. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
1538. Transthyretin chemical chaperoning by flavonoids: Structure–activity insights towards the design of potent amyloidosis inhibitors
1539. Treatment of Alzheimer Disease with Phytochemicals Other Than Curcumin
1540. Treatment of inflammatory bowel disease via green tea polyphenols: Possible application and protective approaches
1541. Troxerutin exerts neuroprotection in 6-hydroxydopamine lesion rat model of Parkinson’s disease: Possible involvement of PI3K/ERβ signaling
1542. Type 2 diabetes mellitus and Alzheimer’s disease: bridging the pathophysiology and management
1543. Tyrosol Reduces Amyloid-β Oligomer Neurotoxicity and Alleviates Synaptic, Oxidative, and Cognitive Disturbances in Alzheimer’s Disease Model Mice
1544. Ulmosides A: flavonoid 6-C-glycosides from Ulmus wallichiana attenuates lipopolysacchride induced oxidative stress, apoptosis and neuronal death
1545. Understanding Alzheimer’s Disease and Other Dementias
1546. UNDERSTANDING PHYTOTHERAPY OF Alzheimer’s DISEASE: LAST DECADE AND COMING FUTURE
1547. Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and Neurodegenerative diseases
1548. Unique properties of polyphenol stilbenes in the brain: more than direct antioxidant actions; gene/protein regulatory activity
1549. Use of Herbal Products/Alternative Medicines in Neurodegenerative Diseases (Alzheimer’s Disease and Parkinson’s Disease)
1550. Validation of neuroprotective action of a commercially available formulation of olive polyphenols in a zebra-fish model vis-a-vis pure hydroxytyrosol
1551. Vanillin attenuated behavioural impairments, neurochemical deficts, oxidative stress and apoptosis against rotenone induced rat model of Parkinson’s disease
1552. Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer’s disease: a new approach to therapy
1553. VISCUM ALBUM ENHANCES BLOOD SERUM BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) LEVEL IN EXPERIMENTAL MODEL OF Alzheimer’s …
1554. Walnut supplementation in the diet reduces oxidative damage and improves antioxidant status in transgenic mouse model of Alzheimer’s disease
1555. What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research
1556. Whole-food diet worsened cognitive dysfunction in an Alzheimer’s disease mouse model
1557. Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson’s and Alzheimer’s disorders?
1558. Wine consumption, cognitive function and dementias–A relationship?
1559. Wine flavonoids in health and disease prevention
1560. Wine phenolics
1561. Wine Polyphenols and Neurodegenerative Diseases: An Update on the Molecular Mechanisms Underpinning Their Protective Effects
1562. Wine polyphenols: potential agents in neuroprotection
1563. Wine-Derived Phenolic Metabolites in the Digestive and Brain Function
1564. Withanolides: biologically active constituents in the treatment of Alzheimer’s disease
1565. Xanthone and flavone derivatives as dual agents with acetylcholinesterase inhibition and antioxidant activity as potential anti-alzheimer agents
1566. Xenobiotic metabolism and berry flavonoid transport across the blood− brain barrier
1567. Zingiber officinale and Alzheimer’s disease: evidences and mechanisms
1568. α-Synuclein Aggregation and Parkinson’s Disease
1569. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson’s disease
1570. α-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesis
1571. α-Synuclein misfolding and Parkinson’s disease
1572. α‐Synuclein oligomers and clinical implications for Parkinson disease
1573. β-Synuclein Assembly as a Therapeutic Target of Parkinson’s Disease and Related Disorders
1574. … -DAD Fingerprinting Analysis, Antioxidant Activity of Phenolic Extracts from Blighia sapida Bark and Its Inhibition of Cholinergic Enzymes Linked to Alzheimer’s …
1575. … -rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson’s disease
1576. … , Biological Evaluation And Molecular Modeling Studies Of Novel Multifunctional neuroprotective Drugs For The Treatment Of Parkinson’s Disease: An Effort …
1577. … , α-Glucosidase, Pancreatic Lipase, Acetyl-and Butyrylcholinesterase Inhibition Activity of Chaenomeles Fruits Determined by Polyphenols and other Chemical …
1578. … acid and E. resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson’s disease: a pharmacoinformatics study
1579. … and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with dementia
1580. … and antioxidant potentials of a medicinal plant Abroma augusta: Implications for the alternative treatment therapy of cognitive deficits in Alzheimer’s disease
1581. … and their acetyl cholinesterase inhibitory and antioxidant activities from leaves of Acanthopanax henryi: potential complementary source against Alzheimer’s disease
1582. … bovine 1SS-alpha-lactalbumin as a model for disease-related amyloidogenic polypeptides: The effects of osmolytes, the flavonoid baicalein, and the GroEL …
1583. … chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: A Preliminary anti- Alzheimer’s study
1584. … chrysin loaded solid lipid nanoparticles against Amyloid β25–35 induced oxidative stress in rat hippocampal region: An efficient formulation approach for Alzheimer’s …
1585. … composition, antioxidant potential and in vitro inhibitory activity of leaves and acorns of Quercus suber on key enzymes relevant for hyperglycemia and Alzheimer’s …
1586. … effects of inhaled Hypericum scabrum L.(Hypericaceae) essential oil against scopolamine-induced Alzheimer’s type dementia/Scopolamine ile oluşturulan …
1587. … effects of water extract of propolis on dopaminergic neurons, brain derived neurotrophic factor, and stress oxidative Factors in the rat model of Parkinson’s …
1588. … efficiency of co-administration of Ginkgo biloba and Trifolium pretense against sodium arsenite-induced neurotoxicity and dementia in different regions of brain and …
1589. … fingerprint analysis, antioxidant properties, and inhibition of cholinergic enzymes (acetylcholinesterase and butyrylcholinesterase) of phenolic extracts from Irvingia …
1590. … flavonoid attenuates cognitive dysfunction and neuronal loss associated with amyloid β (25-35)-induced oxidative stress: an experimental model of Alzheimer’s …
1591. … for the Therapy of Proteinopathies Underlying the Neurodegenerative Conditions: Protein Misfolding and Fibrillization in Alzheimer’s Disease and Parkinson’s …
1592. … from sesame cake reduce oxidative stress and amyloid-β-induced toxicity by upregulation of SKN-1 in a transgenic Caenorhabditis elegans model of Alzheimer’s …
1593. … Impairment Attenuating Effect of Phenolic Compound Rich Fraction of Trianthema portulacastrum in Scopolamine Induced Alzheimer’s Disease Like Condition
1594. … IN THE PREVENTION AND MANAGEMENT OF AGE RELATED Neurodegenerative DISORDERS WITH SPECIAL REFERENCE TO SENILE DEMENTIA
1595. … in tumor necrosis factor like weak inhibitor of apoptosis induced dopaminergic neuronal cell death and microglial activation in invitro and in vivo models of Parkinson …
1596. … INDUCES PKD1 ACTIVATION AND PROTECTS DOPAMINERGIC NEURONS IN CELL CULTURE AND MITOPARK ANIMAL MODELS OF Parkinson’s …
1597. … inhibitory potential and estimation of alkaloids (lycorine and galanthamine) from Crinum species: an important source of anticancer and anti-Alzheimer drug
1598. … KATEKIN GAMBIR TERHADAP KADAR BACE-1 DAN BETA AMYLOID 42 CAIRAN SEREBROSPINAL PADA TIKUS Sprague dawley MODEL ALZHEIMER
1599. … modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s …
1600. … mombim L.(Anacardiaceae): Chemical fingerprints, inhibitory activities, and molecular docking on key enzymes relevant to erectile dysfunction and Alzheimer’s …
1601. … neurorescue against Aβ toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate
1602. … of crude extracts, subsequent fractions, saponins and flavonoids of atriplex laciniata L.: potential effectiveness in Alzheimer’s and other neurological …
1603. … of diagnostic agents, self-assembly inhibitors, and hippocampal transcriptional changes specific to amyloid β-proteinassemblies linked to Alzheimer’s disease
1604. … of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer’s disease mice model
1605. … of flavonoids, baicalein, and daidzein in estrogenic and neuroprotective effects: a development of potential health products and therapeutic drugs against Alzheimer’s …
1606. … of hydroalcoholic extract of Ziziphora clinopodioides L. on spatial memory and neuronal density of hippocampal CA1 region in rats with sporadic Alzheimer’s …
1607. … of iron‐regulated amyloid precursor protein and β‐amyloid peptide by (–)‐epigallocatechin‐3‐gallate in cell cultures: implications for iron chelation in Alzheimer’s …
1608. … of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology …
1609. … OF THE POSSIBLE ANTIOXIDANT EFFECTS OF PEGANUM HARMALA AND GINKGO BILOBA IN AMELIORATING Alzheimer’s DISEASE IN RAT MODEL
1610. … OF ΑLPHA-YNUCLEIN SEEDED NUCLEATION-DEPENDENT AGGREGATION AND TOXICITY AS A POTENTIAL THERAPEUTIC STRATEGY FOR Parkinson’s …
1611. … performance in relation to urinary anthocyanins and their flavonoid-based products following blueberry supplementation in older adults at risk for dementia
1612. … pluricaulis (Shankhapushpi) ameliorates human microtubule-associated protein tau (hMAPτ) induced neurotoxicity in Alzheimer’s disease Drosophila model
1613. … pyrroloquinolinequinone-containing dietary formulation on motor deficiency, cognitive decline and mitochondrial dysfunction in a mouse model of Alzheimer’s …
1614. … STRESS, NEUROINFLAMMATION AND NEURODEGENERATION AGAINST LIPOPOLYSACCHARIDE-INDUCED Alzheimer’s DISEASE VIA JNK-3 AND …
1615. … the brain functions by bitter (Vernonia amygdalina) and water bitter (Struchium sparganophora) leaves extracts: comparison of phenolic constituents versus nootropic …
1616. … the functional diversity of flavonoids derived from Chinese Materia Medica: Drug developments for the prevention of Alzheimer’s disease and osteoporosis
1617. … with HPLC-FTMS of exogenous and endogenous chemicals susceptible to the administration of chotosan in an animal model of type 2 diabetes-induced dementia
1618. “A GREAT PERTURBATION IN NATURE”-Parkinson’s DISEASE AND SLEEP DISORDERS–
1619. “Polyphenolic-food” Effects on Brain Health (Human Data review)
1620. 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine is a potent neurotoxin: Gamma-tocopherol recuperate behavior, dopamine, and oxidative stress on Parkinsonic …
1621. 10. neuroprotective effects of oxyresveratrol from fruit against neurodegeneration in Alzheimer’s disease
1622. 15 Alzheimer’s Disease and Other Forms of Dementia
1623. 15 Apple Phenolics and Alzheimer’s Disease
1624. 15 Botanical Phenolics and Neurodegeneration
1625. 15 Dietary flavonoids as neuroprotective Agents
1626. 15 Green Tea Flavan-3-ols
1627. 16 Actions of Bioactive Phytochemicals in Cell Function and Alzheimer’s Disease Pathology
1628. 17 Effects of flavonoids on Cognitive Performance
1629. 19 Natural Phenolics and Metal Metabolism in Neurodegenerative Diseases
1630. 19 The neuroprotective Capacity of Achyrocline satureioides (Lam) DC and Its Flavonoids
1631. 2 Direct Evaluation of Alzheimer’s Disease-Specific oxidative stress with Multiphoton Microscopy
1632. 3, 5, 4′-trihydroxy-6, 7, 3′-trimethoxyflavone protects against beta amyloid-induced neurotoxicity through antioxidative activity and interference with cell …
1633. 4 Coffee and Alzheimer’s Disease: Animal and Cellular Evidence
1634. 6 neuroprotective Mechanisms: oxidative stress as a Target for neuroprotective Therapies in Alzheimer’s and Parkinson’s
1635. 6-Shogaol has neuroprotective Effects in Parkinson’s Disease Model
1636. 7, 8-Dihydroxyflavone as a pro-neurotrophic treatment for neurodevelopmental disorders
1637. 7, 8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders
1638. 8 Neuroprotection by Dietary and Citrus Flavonoids
1639. A blueberry-enriched diet provides cellular protection against oxidative stress and reduces a kainate-induced learning impairment in rats
1640. A botanical containing freeze dried açai pulp promotes healthy aging and reduces oxidative damage in sod1 knockdown flies
1641. A brief review on the neuroprotective mechanisms of vitexin
1642. A Close Look at Echium amoenum Processing, Neuroactive Components, and Effects on Neuropsychiatric Disorders
1643. A cocoa peptide protects Caenorhabditis elegans from oxidative stress and β-amyloid peptide toxicity
1644. A Combination of Green Tea Extract and l-Theanine Improves Memory and Attention in Subjects with Mild Cognitive Impairment: A Double-Blind Placebo-Controlled …
1645. A comparative study of the in vitro enzyme inhibitory and antioxidant activities of Butea monosperma (Lam.) Taub. and Sesbania grandiflora (L.) Poiret from Pakistan …
1646. A comparative study on the antioxidant and immunomodulatory properties of curcumin conjugated gold nanospheres and free curcumin
1647. A comparative thin layer chromatography study of different brands of five herbal remedies
1648. A Comparison of Inhibitory Effects on Catecholamine Secretion between CGP42112 and CGP42112 plus PD123319
1649. A comparison of the efficacy and tolerability of interferon-beta (INFb) products used as initial or follow-up therapy for the treatment of relapsing multiple sclerosis …
1650. A Comprehensive Insight on the Health Benefits and Phytoconstituents of Camellia sinensis and Recent Approaches for Its Quality Control
1651. A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases
1652. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies
1653. A crosssectional study of ethnopharmacology in the Noakhali district of Bangladesh and exploring potential ocular immunostimulatory activity of the medicinal …
1654. A current perspective on the inhibition of cholinesterase by natural and synthetic inhibitors
1655. A current update on phytochemistry, pharmacology and herb–drug interactions of Hypericum perforatum
1656. A diet for dopaminergic neurons?
1657. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of …
1658. A life-course contribution of nutrition to future cognitive decline
1659. A Mini Review on the Protective Effect of Lignans for the Treatment of Neurodegenerative Disorders
1660. A mixture of fucoxanthin and punicic acid prevents obesity in high-fat diet-induced obese mice
1661. A New Therapeutic Concept of LMT356 for Stroke Therapy: Extension of the Thrombolytic Time Window of tPA
1662. A Novel Approach towards Nutraceuticals and Biomedical Applications
1663. A Novel neuroprotective and Antioxidative Efficacy of a Unique Combination of Standardized Huperzia serrata, Convolvulus pluricaulis and Celastrus …
1664. A pharmacognostic and pharmacological review on Vigna aconitifolia (Moth bean)
1665. A Pharmacological Review of Bioactive Constituents of Paeonia lactiflora Pallas and Paeonia veitchii Lynch
1666. A Pilot Study to Evaluate Chemopreventive Effects of Blueberry (Vaccinium spp.)
1667. A Polysaccharide Produced by a New Streptomyces Strain Modulates Immunological Activity in RAW264. 7 Cells
1668. A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects
1669. A possible role for π-stacking in the self-assembly of amyloid fibrils
1670. A potential alternative against Neurodegenerative diseases: Phytodrugs
1671. A Potential Natural Product Combination Targeting Memory Disorders
1672. A randomized controlled trial investigating the effect of Pycnogenol and Bacopa CDRI08 herbal medicines on cognitive, cardiovascular, and biochemical …
1673. A redox-active, compact molecule for cross-linking amyloidogenic peptides into nontoxic, off-pathway aggregates: in vitro and in vivo efficacy and molecular …
1674. A refined concept: α-synuclein dysregulation disease
1675. A review of dietary Ziziphus jujuba fruit (Jujube): developing health food supplements for brain protection
1676. A review of Neuropharmacology Effects of Nigella sativa and Its Main Component, Thymoquinone
1677. A review of neuroprotective agents
1678. A Review of neuroprotective Agents
1679. A review of some medicinal plants used for nervous disorders
1680. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to Neurodegenerative processes
1681. A review of the medicinal properties and applications of Pycnanthus angolensis (Welw) Warb
1682. A review of the pharmacology and toxicology of aucubin
1683. A review of the role of green tea (Camellia sinensis) in antiphotoaging, stress resistance, neuroprotection, and autophagy
1684. A review of therapeutic effects of curcumin
1685. A review of three commonly used herbs which enhance memory and new evidences which show their combination could improve memory in young animals
1686. A review on ethnomedicinal, phytochemical, and pharmacological significance of Terminalia sericea Burch. Ex DC.
1687. A review on medicinal importance, pharmacological activity and toxicology of ”Nutraceuticals”
1688. A review on medicinal properties of saffron toward major diseases
1689. A Review on Natural Antioxidants
1690. A review on natural memory enhancers (Nootropics)
1691. A Review on Neuronutrition
1692. A review on nutraceuticals: classification and its role in various diseases
1693. A Review on Pharmaceutically Important Medicinal plant: Bacopa monnieri
1694. A Review on Phytochemistry and Pharmacology of Otostegia persica (Burm. f.) Boiss.
1695. A review on possible therapeutic effect of Nigella sativa and thymoquinone in Neurodegenerative diseases
1696. A review on spikenard (Nardostachys jatamansi DC.)-an ‘endangered’essential herb of India
1697. A review on the phytopharmacological studies of the genus Polygala
1698. A review on the possible neuroprotective effects of Moringa oleifera leaf extract
1699. A Review on Therapeutic Potentials of Crocetin-A Carotenoid Derived from Saffron
1700. A review on therapeutic potentials of Trigonella foenum graecum (fenugreek) and its chemical constituents in neurological disorders: Complementary roles to its …
1701. A review on traditional uses, phytochemistry and pharmacology of Eclipta prostrata (L.) L.
1702. A review study on medicinal plants affecting amnesia through cholinergic system
1703. A Role for Activated Microglia and Peroxynitrite in Lewy Body Diseases–Implications for Prevention and Control
1704. A Role for Orexin Neuron Activity in Cytotoxic Chemotherapy-Induced Fatigue
1705. A Role of Gallic Acid in Oxidative Damage Diseases: A Comprehensive Review
1706. A simple and efficient HPLC method for quantitative analysis of Gingkolides extracted from Ginkgonis Semen
1707. A Splicing Variant of AIMP2 as a Therapeutic Controller for Neurodegenerative Diseases
1708. A status review on the medicinal properties of essential oils
1709. A STUDY ON ANTI-INFLANNATORY AND neuroprotective EFFECTS OS COSTUNOLIDE ON LIPOPOLYSACCHARIDE ACTIVATED MURINE BRAIN …
1710. A STUDY ON CNS EFFECTS OF MILK EXTRACT OF NUTS OF SEMECARPUS ANACARDIUM. LINN,(ANACARDIACEAE).
1711. A study on nephroprotectiveness and pharmacokinetic properties of selected nutraceuticals and evaluation of chronic renal failure inducing model for their …
1712. A Synthetic Snake-Venom-Based Tripeptide Protects PC12 Cells from the Neurotoxicity of Acrolein by Improving Axonal Plasticity and Bioenergetics
1713. A systematic and comprehensive review on Withania somnifera (L.) dunal-an indian ginseng
1714. A systematic Approach to Evaluate Herb-drug Interaction Mechanisms: Investigation of a Purified Ginseng Extracts
1715. A systematic overview of the scientific literature on the association between Mediterranean Diet and the Stroke prevention
1716. A systematic review on Piper longum L.: Bridging traditional knowledge and pharmacological evidence for future translational research
1717. A systematic review on the vocational pharmacy education and pharmacists’ role in the Singapore’s healthcare system
1718. A therapeutic connection between dietary phytochemicals and ATP synthase
1719. A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds
1720. AARP Prescription for Drug Alternatives: All Natural Options for Better Health without the Side Effects
1721. AARP The Immortality Edge: Realize the Secrets of Your Telomeres for a Longer, Healthier Life
1722. ABC transporters and drug efflux at the blood-brain barrier
1723. Açaí: An Extraordinary Antioxidant-Rich Palm Fruit
1724. Acanthus ebracteatus leaf extract provides neuronal cell protection against oxidative stress injury induced by glutamate
1725. Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats
1726. Acer okamotoanum protects SH-SY5Y neuronal cells against hydrogen peroxide-induced oxidative stress
1727. Acetyl cholinesterase inhibition potential and antioxidant activities of ferulic acid isolated from Impatiens bicolor Linn
1728. Acetylcholinesterase from human erythrocytes membrane: a screen for evaluating the activity of some traditional plant extracts
1729. Acetylcholinesterase inhibition and antioxidant activities of polysaccharide-peptide complexes from edible mushrooms
1730. Acetylcholinesterase inhibition and antioxidant activity of Syzygium cumini, S. aromaticum and S. polyanthum from Indonesia
1731. Acetylcholinesterase inhibition and in vitro and in vivo antioxidant activities of Ganoderma lucidum grown on germinated brown rice
1732. Acetylcholinesterase inhibition by medicinal plants: A Review
1733. Acetylcholinesterase Inhibition, Antioxidant, Antiinflammatory, Antimicrobial and Phytochemical Properties of Huernia hystrix
1734. Acetylcholinesterase inhibitors of natural origin
1735. Acetylcholinesterase Inhibitory Activity and Antioxidant Activity of Selected Medicinal Plant Extracts Used Against Cognitive Dysfunction and Memory Loss in Sri …
1736. Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products
1737. Acetylcholinesterase inhibitory and antioxidant properties of root extract from Pueraria mirifica
1738. Acetylcholinesterase inhibitory effect of capsicum oleoresins–an in vitro study
1739. Acetylcholinesterase Inhibitory Potential and Insecticidal Activity of an Endophytic Alternaria sp. from Ricinus communis
1740. Acetylcholinesterase inhibitory potentiality of some minor fruits of West Bengal, India
1741. Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal plants of the Lamiaceae family
1742. Acetylcholineterase inhibitory and antioxidant properties of Rhododendron yedoense var. Poukhanense bark
1743. Achillea fragrantissima: Pharmacology Review
1744. Acid Intake, Delivered Via Moderate Champagne Wine Consumption, Improves Spatial Working Memory Via the Modulation of Hippocampal and Cortical …
1745. Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases
1746. Activation of anti-oxidant of curcumin pyrazole derivatives through preservation of mitochondria function and Nrf2 signaling pathway
1747. Activation of Autophagy by Globular Adiponectin Protects against Ethanolinduced Apoptosis in HepG2 Cells
1748. Activation of Protease-activated Receptor 2 through Gastric Refluxants Stimulates Proliferation and Interleukin (IL)-6, IL-8 and Matrix Metallopeptidase (MMP) …
1749. Activation of the NRF2 Pathway in Non-adherent Mammosphere Culture System
1750. Acute administration of Ginkgo biloba extract (EGb 761) affords neuroprotection against permanent and transient focal cerebral ischemia in Sprague‐Dawley rats
1751. Acute and Chronic Exercise Effects on NrF2 and Antioxidants in the Muscle and Brain Tissue of Sprague Dawley Rats
1752. Acute Autophagy-Dependent Non-inflammatory Epithelial Death Plays as an Intrinsic Defense to Bacteria
1753. Acute neurocognitive effects of epigallocatechin gallate (EGCG)
1754. Add Life to Your Years & Years To Your Life: Experience New Energy, Strength & Vitality to Age Gracefully, Joyfully & Healthily
1755. Adenosine monophosphate (AMP)-activated protein kinase: a new target for nutraceutical compounds
1756. Adherence to Mediterranean diet and subjective cognitive function in men
1757. Adiponectin Modulates Anti-Inflammatory MicroRNA Expression in RAW 264.7 Macrophages
1758. Administration of chinpi, a component of the herbal medicine ninjin-youei-to, reverses age-induced demyelination
1759. Advanced chemometric modeling approaches for the design of multitarget drugs against Neurodegenerative diseases
1760. Advanced Glycation Endproducts (AGEs) in Food: Health Implications and Mitigation Strategies
1761. Advanced glycation endproducts: what is their relevance to diabetic complications?
1762. Advances in Date Palm (Phoenix dactylifera L.) Breeding
1763. Advances in drug discovery to assess cholinergic neurotransmission: a systematic review
1764. Advances in Nutraceuticals
1765. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases
1766. Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein
1767. Advances in therapeutics for Neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species
1768. Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors
1769. Advancing medicine with food and nutrients
1770. Advancing neuroprotective-based treatments for schizophrenia
1771. Advocacy in Geriatric Neurology
1772. Aerobic exercise, diet, and neurocognition among individuals with high blood pressure
1773. African medicinal plants acting on the reproductive, cardiovascular, and central nervous systems
1774. Age before beauty
1775. Age-related deficits in electron transport chain complexes in rat neurons and 3xTg-AD mouse neurons
1776. Age-related differences in stress response: Increase markers for oxidative stress and liver damage after heat stress in aged rats?
1777. Age-related epigenetic drift and phenotypic plasticity loss: implications in prevention of age-related human diseases
1778. Age-Related Neurodegenerative
1779. Age-related oxidative protein damages in central nervous system of rats: modulatory role of grape seed extract
1780. Ageing and eating
1781. Ageing and Neurodegenerative diseases
1782. Ageing, cellular senescence and Neurodegenerative disease
1783. Ageing: biology and nutrition
1784. Ageless Brain: Think Faster, Remember More, and Stay Sharper by Lowering Your Brain Age
1785. Aging and Microglial Activation in Neurodegenerative Diseases
1786. Aging and the cerebral microvasculature: clinical implications and potential therapeutic interventions
1787. Aging is not a disease: implications for intervention
1788. Aging microglia: relevance to cognition and neural plasticity
1789. Aging without growing old
1790. Aging, Nutrition and Taste: Nutrition, Food Science and Culinary Perspectives for Aging Tastefully
1791. Aging: an important factor for the pathogenesis of Neurodegenerative diseases
1792. Aging: minimizing free radical damage
1793. AIMP1 as a Modulator of Immune Functions and Pharmacological Implications
1794. Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies
1795. Alcohol, ageing and cognitive function: a nutritional perspective
1796. Alkaloids from Peumus boldus and their Acetylcholinesterase, Butyrylcholinesterase and Prolyl Oligopeptidase Inhibition Activity
1797. Allergen-specific memory CD4 T cells require IL-7 signaling for its homeostasis in mediastinal lymph node
1798. Allergic Asthma Pathogenesis and Antioxidant Therapy
1799. Almonds and brain functionality
1800. Alpha-lipoic acid and mesuagenin c-induced co-regulation of nf-κβ-cytokines and chemokines via pi3k-akt/gsk-3β and erk1/2 in in vitro neuronal models/Muhamad …
1801. Alpha-synuclein suppresses retinoic acid-induced neuronal differentiation by targeting the glycogen synthase kinase-3β/β-catenin signaling pathway
1802. Alpha-Synuclein-Induced Dysregulation of Neuronal Differentiatio
1803. Alpha-synuclein, oxidative stress and autophagy failure: dangerous liaisons in dopaminergic neurodegeneration
1804. Alteration of cholesterol homeostasis in the Huntington’s disease brain
1805. Altered brain metabolism of iron as a cause of Neurodegenerative diseases?
1806. Aluminium (III) as a promoter of cellular oxidation
1807. Aluminum Induced Reproductive Dysfunction in Male Rats: The Ameliorative Effect of Saffron Extract
1808. Always Eat After 7 PM: The Revolutionary Rule-Breaking Diet That Lets You Enjoy Huge Dinners, Desserts, and Indulgent Snacks—While Burning Fat …
1809. Amazing Bible Healing Plants, Remedies and Recipes
1810. Amazing Health Benefits of Green Tea
1811. Amelioration of oxidative stress in differentiated neuronal cells by rutin regulated by a concentration switch
1812. Amelioration of scopolamine-induced learning and memory impairment by 𝛼-Pinene in C57BL/6 mice
1813. Amelioration of the Impact of Physical Fatigue on Cognitive Performance by Phytochemicals: The Effect of a Blackcurrant Supplement: A thesis presented in partial …
1814. Ameliorative Effects of ferulic acid against lead acetate-induced oxidative stress, mitochondrial dysfunctions and toxicity in prepubertal rat brain